Axon Enterprise (AXON) 10-K 6 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Feb. 15, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	TASER INTERNATIONAL INC
Entity Central Index Key	1,069,183
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,334,648
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,273

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 40,651	$ 59,526
Short-term investments	48,415	50,254
Accounts and notes receivable, net of allowance of $443 and $322 as of December 31, 2016 and 2015, respectively	39,466	27,701
Inventory	34,841	15,763
Prepaid expenses and other current assets	13,858	8,165
Total current assets	177,231	161,409
Property and equipment, net	24,004	21,848
Deferred income tax assets, net	19,515	13,719
Intangible assets, net	15,218	7,588
Goodwill	10,442	9,596
Long-term investments	234	8,525
Long-term accounts and notes receivable, net of current portion	17,602	1,227
Other assets	13,917	5,969
Total assets	278,163	229,881
Current liabilities:
Accounts payable	10,736	7,333
Accrued liabilities	18,248	8,643
Current portion of deferred revenue	45,137	20,851
Customer deposits	2,148	1,226
Current portion of business acquisition contingent consideration	1,690	0
Other current liabilities	80	87
Total current liabilities	78,039	38,140
Deferred revenue, net of current portion	40,054	30,190
Liability for unrecognized tax benefits	1,896	1,315
Long-term deferred compensation	3,362	2,199
Business acquisition contingent consideration, net of current portion	1,635	952
Other long-term liabilities	2,289	81
Total liabilities	127,275	72,877
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of December 31, 2016 and 2015	0	0
Common stock, $0.00001 par value; 200,000,000 shares authorized; 52,325,251 and 53,692,192 shares issued and outstanding as of December 31, 2016 and 2015, respectively	1	1
Additional paid-in capital	187,656	178,143
Treasury stock at cost, 20,220,227 and 18,432,158 shares as of December 31, 2016 and 2015, respectively	(155,947)	(122,201)
Retained earnings	118,275	100,978
Accumulated other comprehensive income	903	83
Total stockholders’ equity	150,888	157,004
Total liabilities and stockholders’ equity	$ 278,163	$ 229,881

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance on accounts receivable	$ 443	$ 322
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	52,325,251	53,692,192
Common stock, shares outstanding	52,325,251	53,692,192
Treasury stock, shares	20,220,227	18,432,158

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Net sales	$ 268,245	$ 197,892	$ 164,525
Cost of products sold and services delivered	97,709	69,245	62,977
Gross margin	170,536	128,647	101,548
Operating expenses:
Sales, general and administrative	108,076	69,698	54,158
Research and development	30,609	23,614	14,885
Total operating expenses	138,685	93,312	69,043
Income from operations	31,851	35,335	32,505
Interest and other income (expense), net	(354)	26	(194)
Income before provision for income taxes	31,497	35,361	32,311
Provision for income taxes	14,200	15,428	12,393
Net income	$ 17,297	$ 19,933	$ 19,918
Net income per common and common equivalent shares:
Basic (in dollars per share)	$ 0.33	$ 0.37	$ 0.38
Diluted (in dollars per share)	$ 0.32	$ 0.36	$ 0.37
Weighted average number of common and common equivalent shares outstanding:
Basic (in shares)	52,667	53,548	52,948
Diluted (in shares)	53,536	54,638	54,500
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	$ 17,297	$ 19,933	$ 19,918
Foreign currency translation adjustments	820	19	66
Comprehensive income	$ 18,117	$ 19,952	$ 19,984

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Beginning balance, Shares at Dec. 31, 2013		52,725,247		16,412,755
Beginning balance at Dec. 31, 2013	$ 108,347	$ 1	$ 139,424	$ (92,203)	$ (2)	$ 61,127
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised and RSUs vested, net of withholdings, Shares		2,002,823
Stock options exercised and RSUs vested, net of withholdings	9,653		9,653
Stock-based compensation	5,579		5,579
Excess tax benefit from stock-based compensation	7,985		7,985
Purchase of treasury stock, Shares		(1,727,203)		1,727,203
Purchase of treasury stock	(22,442)			$ (22,442)
Net income	19,918					19,918
Foreign currency translation adjustments	66				66
Ending balance, Shares at Dec. 31, 2014		53,000,867		18,139,958
Ending balance at Dec. 31, 2014	129,106	$ 1	162,641	$ (114,645)	64	81,045
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised and RSUs vested, net of withholdings, Shares		983,525
Stock options exercised and RSUs vested, net of withholdings	1,303		1,303
Stock-based compensation	7,263		7,263
Excess tax benefit from stock-based compensation	6,936		6,936
Purchase of treasury stock, Shares		(292,200)		292,200
Purchase of treasury stock	(7,556)			$ (7,556)
Net income	19,933					19,933
Foreign currency translation adjustments	19				19
Ending balance, Shares at Dec. 31, 2015		53,692,192		18,432,158
Ending balance at Dec. 31, 2015	157,004	$ 1	178,143	$ (122,201)	83	100,978
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised and RSUs vested, net of withholdings, Shares		421,128
Stock options exercised and RSUs vested, net of withholdings	(1,294)		(1,294)
Stock-based compensation	9,369		9,369
Excess tax benefit from stock-based compensation	1,438		1,438
Purchase of treasury stock, Shares		(1,788,069)		1,788,069
Purchase of treasury stock	(33,746)			$ (33,746)
Net income	17,297					17,297
Foreign currency translation adjustments	820				820
Ending balance, Shares at Dec. 31, 2016		52,325,251		20,220,227
Ending balance at Dec. 31, 2016	$ 150,888	$ 1	$ 187,656	$ (155,947)	$ 903	$ 118,275

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income	$ 17,297	$ 19,933	$ 19,918
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,658	3,291	4,317
Purchase accounting adjustments to goodwill	520	0	0
Loss (gain) on disposals of property and equipment, net	42	(19)	17
Loss on disposal of intangible assets	21	225	215
Bond premium amortization	1,265	1,650	957
Stock-based compensation	9,369	7,263	5,579
Deferred income taxes	(5,167)	994	3,598
Unrecognized tax benefits	582	(156)	202
Tax benefit from stock-based compensation	(1,438)	(6,936)	(7,985)
Change in assets and liabilities:
Accounts and notes receivable	(13,297)	4,244	(8,247)
Inventory	(18,668)	3,140	(7,214)
Prepaid expenses and other assets	(29,069)	(8,579)	(1,080)
Accounts payable, accrued and other liabilities	17,584	5,868	9,852
Deferred revenue	34,304	15,289	15,469
Customer deposits	922	238	(166)
Net cash provided by operating activities	17,925	46,445	35,432
Cash flows from investing activities:
Purchases of investments	(56,086)	(62,464)	(32,900)
Proceeds from call / maturity of investments	64,951	44,105	10,997
Purchases of property and equipment	(4,957)	(6,003)	(2,505)
Proceeds from disposal of property and equipment	42	40	10
Purchases of intangible assets	(3,495)	(501)	(183)
Business acquisitions, net of cash acquired	(3,500)	(11,186)	0
Net cash used in investing activities	(3,045)	(36,009)	(24,581)
Cash flows from financing activities:
Repurchase of common stock	(33,746)	(7,556)	(22,442)
Proceeds from options exercised	478	2,673	11,000
Payroll tax payments for net-settled stock awards	(1,772)	(1,370)	(1,347)
Payments on capital lease obligation	(32)	(80)	(36)
Payments on notes payable	(75)	0	0
Payment of contingent consideration for business acquisition	(952)	0	0
Excess tax benefit from stock-based compensation	1,438	6,936	7,985
Net cash (used in) provided by financing activities	(34,661)	603	(4,840)
Effect of exchange rate changes on cash and cash equivalents	906	120	85
Net increase (decrease) in cash and cash equivalents	(18,875)	11,159	6,096
Cash and cash equivalents, beginning of year	59,526	48,367	42,271
Cash and cash equivalents, end of year	$ 40,651	$ 59,526	$ 48,367

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies TASER International, Inc. (“TASER” or the “Company”) is a developer and manufacturer of advanced conducted electrical weapons (“CEWs”) designed for use by law enforcement, military, corrections, and private security personnel, and by private individuals for personal defense. In addition, the Company has developed full technology solutions for the capture, storage and management of video/audio evidence as well as other tactical capabilities for use in law enforcement. The Company sells its products worldwide through its direct sales force, distribution partners, online store and third-party resellers. The Company was incorporated in Arizona in September 1993, and reincorporated in Delaware in January 2001. The Company’s corporate headquarters and manufacturing facilities are located in Scottsdale, Arizona. The Company’s software development unit facility is located in Seattle, Washington. TASER International BV, a wholly owned subsidiary of the Company, serves as the Company's international headquarters, and is located in Amsterdam, Netherlands. The accompanying consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries, including TASER International Europe SE (“TASER Europe”), TASER International B.V., Axon Public Safety Canada, and MediaSolv Solutions Corporation ("MediaSolv"). All material intercompany accounts, transactions, and profits have been eliminated. a. Basis of Presentation and Use of Estimates The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions in these consolidated financial statements include: • product warranty reserves, • inventory valuation, • revenue recognition allocated in multiple-deliverable contracts or arrangements, • valuation of goodwill, intangibles and long-lived assets, • recognition, measurement and valuation of current and deferred income taxes, • recognition and measurement of contingencies and accrued litigation expense. and • fair value of stock awards issued, the estimated vesting period for performance-based stock awards and forfeiture rates, Actual results could differ materially from those estimates. b. Cash, Cash Equivalents and Investments Cash, cash equivalents and investments include cash, money market funds, certificates of deposit, state and municipal obligations and corporate bonds. The Company places its cash and cash equivalents with high quality financial institutions. Although the Company deposits its cash with multiple financial institutions, its deposits, at times, may exceed federally insured limits. Cash and cash equivalents include funds on hand and highly liquid investments purchased with initial maturity of three months or less. Short-term investments include securities with an expected maturity date within one year of the balance sheet date that do not meet the definition of a cash equivalent, and long-term investments are securities with an expected maturity date greater than one year. Based on management’s intent and ability, the Company’s investments are classified as held to maturity investments and are recorded at amortized cost. Held-to-maturity investments are reviewed quarterly for impairment to determine if other-than-temporary declines in the carrying value have occurred for any individual investment. Other-than-temporary declines in the value of held-to-maturity investments are recorded as expense in the period the determination is made. c. Inventory Inventories are stated at the lower of cost or market. Cost is determined using the weighted average cost of raw materials which approximates the first-in, first-out (“FIFO”) method and includes allocations of manufacturing labor and overhead. Provisions are made to reduce potentially excess, obsolete or slow-moving inventories to their net realizable value. These provisions are based on management’s best estimate after considering historical demand, projected future demand, inventory purchase commitments, industry and market trends and conditions and other factors. Management evaluates inventory costs for abnormal costs due to excess production capacity and treats such costs as period costs. d. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. Additions and improvements are capitalized, while ordinary maintenance and repair expenditures are charged to expense as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. e. Software Development Costs The Company expenses software development costs, including costs to develop software products or the software component of products to be marketed to external users, before technological feasibility of such products is reached. The Company has determined that technological feasibility is reached shortly before the release of those products and as a result, the development costs incurred after the establishment of technological feasibility and before the release of those products are not material. Software development costs also include costs to develop software programs to be used solely to meet the Company's internal needs and cloud-based applications used to deliver its services. The Company capitalizes development costs related to these software applications once the preliminary project stage is complete and it is probable that the project will be completed and the software will be used to perform the intended function. Additionally, the Company capitalizes qualifying costs incurred for upgrades and enhancements to existing software that result in additional functionality. Costs related to preliminary project planning activities, post-implementation activities, maintenance and minor modifications are expensed as incurred. Internal-use software is amortized on a straight line basis over its estimated useful life. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. f. Valuation of Goodwill, Intangibles and Long-lived Assets The Company does not amortize goodwill and intangible assets with indefinite useful lives, rather such assets are required to be tested for impairment at least annually during the fourth quarter or sooner whenever events or changes in circumstances indicate that the assets may be impaired. Finite-lived intangible assets and other long-lived assets are amortized over their useful lives. Management evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and intangible assets may warrant revision or that the remaining balance of these assets, including intangible assets with indefinite lives, may not be recoverable. Circumstances that might indicate long-lived assets might not be recoverable could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way the Company's products are branded and marketed. When performing a review for recoverability, management estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows. No impairment losses were recorded during the years ended December 31, 2016 , 2015 and 2014 . g. Customer Deposits The Company requires deposits in advance of shipment for certain customer sales orders. Customer deposits are recorded as a current liability in the accompanying consolidated balance sheets. h. Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable The Company derives revenue from two primary sources: (1) the sale of physical products, including CEWs, Axon cameras, corresponding extended warranties, and related accessories such as Axon Docks, cartridges and batteries, among others, and (2) subscription to the Company's Evidence.com software as a service ("SaaS") (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, the Company also recognizes training and other professional services revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Contractual arrangements may contain explicit customer acceptance provisions, and under such arrangements, the Company defers recognition of revenue until formal customer acceptance is received. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract. Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price or third-party evidence of the selling prices if vendor-specific objective evidence of selling prices does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price. The majority of the Company’s allocations of arrangement consideration under multiple element arrangements are performed using vendor-specific objective evidence by utilizing prices charged to customers for deliverables when sold separately. The Company’s multiple element arrangements may include future CEWs and/or Axon devices to be delivered at defined points within a multi-year contract, and in those arrangements, the Company allocates total arrangement consideration over the life of the multi-year contract to future deliverables using management’s best estimate of selling price. The Company has not utilized third-party evidence of selling price. The Company offers the right to purchase extended warranties that include additional services and coverage beyond the standard limited warranty for certain products. Revenue for extended warranty purchases is deferred at the time of sale and recognized over the warranty period commencing on the date of sale. Extended warranties range from one to five years. Evidence.com and Axon cameras and related accessories have stand-alone value to the customer and are sometimes sold separately, but in most instances are sold together. In these instances, customers typically purchase and pay for the equipment and one year of Evidence.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. Generally, the Company recognizes revenue for the Axon equipment at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for Evidence.com is deferred at the time of the sale and recognized over the service period. At times the Company subsidizes the cost of Axon devices provided to customers to secure long-term Evidence.com service contracts. In such circumstances, revenue related to the Axon devices recognized at the time of delivery is limited to the amount collected from the customer that is not contingent upon the delivery of future Evidence.com services. The Company recognizes the remaining allocated revenue related to subsidized Axon devices over the remaining period it provides the contracted Evidence.com services. In 2012, the Company introduced a program, the TASER Assurance Program (“TAP”) whereby a customer purchasing a product and joining the program will have the right to trade-in the original product for a new product of the same or like model in the future. Upon joining TAP, customers also receive an extended warranty for the initial products purchased and spare inventory. Under this program the customer generally pays additional annual installments over the contract period, generally three to five years. The Company records consideration received related to the future product purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the new product is delivered. Consideration related to future product purchases is determined at the inception of the arrangement using management’s best estimate of selling price. Management’s estimate is principally based on the current selling price for such products, with due evaluation of the impact of any expected product and pricing changes, which have historically had an immaterial influence on management’s best estimate of selling price. In 2015, The Company introduced the Officer Safety Plan (“OSP”), whereby a customer typically enters into a five year Evidence.com subscription that includes all of its standard advanced features along with unlimited storage. The OSP also includes a service plan that includes upgrades of (i) the Axon devices every 2.5 years and (ii) a TASER CEW at any point within the contract period. Upon entering into the OSP, customers also receive extended warranties on the Axon and CEW devices over the five -year contract periods as well as spare inventory units. Under this program the customer generally makes an initial purchase of Axon cameras and related accessories, and CEWs at inception and pays the first of its annual installments for services and future hardware deliverables over the contract period. The Company records consideration received related to the future purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the products or services are delivered. In 2016, the Company introduced the TASER 60 Plan ("TASER 60") whereby a customer typically enters into a five year CEW installment purchase arrangement. The TASER 60 plan also includes extended warranties on the CEW devices upon delivery covering the contract periods as well as on-site spares, holsters and cartridges. Generally, the Company recognizes revenue for the amount allocated to the CEW at the time of sale for the amount of the customer receivable, net of imputed interest, and the amount allocated to the extended warranty is recognized over five years. Sales tax collected on sales is netted against government remittances and thus, recorded on a net basis. Training revenue is recorded as the service is provided. Deferred revenue consists of payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. Generally, customers are billed in annual installments. See Note 7 for further disclosures about of the Company’s deferred revenue. Sales are typically made on credit and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for estimated potential losses. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents management’s best estimate and is based on their judgment after considering a number of factors, including third-party credit reports, actual payment history, cash discounts, customer-specific financial information and broader market and economic trends and conditions. i. Cost of Products Sold and Services Provided Cost of products sold represents manufacturing costs, consisting of materials, labor and overhead related to finished goods and components. Shipping costs incurred related to product delivery are also included in cost of products sold. Cost of services delivered includes third-party cloud services, and software maintenance and support costs, including personnel costs, associated with supporting Evidence.com. j. Advertising Costs The Company expenses advertising costs in the period in which they are incurred. The Company incurred advertising costs of $0.4 million , $0.6 million and $0.3 million in the years ended December 31, 2016 , 2015 and 2014 , respectively. Advertising costs are included in sales, general and administrative expenses in the accompanying statements of operations. k. Standard Warranties The Company warranties its CEWs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to returns and warranty costs on a quarterly basis and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure that could result in larger than anticipated returns from customers. The accrued warranty liability expense is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred. The reserve for warranty returns is included in accrued liabilities on the accompanying consolidated balance sheets. Changes in the Company’s estimated product warranty liabilities were as follows (in thousands): 2016 2015 2014 Balance, January 1 $ 314 $ 675 $ 955 Utilization of accrual (155 ) (299 ) (676 ) Warranty expense (recoveries) 621 (62 ) 396 Balance, December 31 $ 780 $ 314 $ 675 l. Research and Development Expenses The Company expenses as incurred research and development costs that do not meet the qualifications to be capitalized. The Company incurred research and development expense of $30.6 million , $23.6 million and $14.9 million , in 2016 , 2015 and 2014 , respectively. m. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in future years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced through the establishment of a valuation allowance if, based upon available evidence, it is determined that it is more likely than not that the deferred tax assets will not be realized. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. Management also assesses whether uncertain tax positions, as filed, could result in the recognition of a liability for possible interest and penalties. The Company’s policy is to include interest and penalties related to unrecognized tax benefits as a component of income tax expense. Refer to Note 10 for additional information regarding the change in unrecognized tax benefits. n. Concentration of Credit Risk and Major Customers / Suppliers Financial instruments that potentially subject the Company to concentrations of credit risk consist of accounts and notes receivable and cash. Sales are typically made on credit and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for estimated losses. Uncollectible accounts are written off when deemed uncollectible, and accounts receivable are presented net of an allowance for doubtful accounts, which totaled $0.4 million and $0.3 million as of December 31, 2016 and 2015 , respectively. Historically, the Company has experienced a low level of write-offs related to doubtful accounts. The Company maintains the majority of its cash and cash equivalents accounts at five depository institutions. As of December 31, 2016 , the aggregate balances in such accounts were $33.2 million . The Company’s balances with these institutions regularly exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits for domestic deposits and various deposit insurance programs covering our deposits in the Netherlands, the United Kingdom, Germany and Australia. To manage the related credit exposure, management continually monitors the creditworthiness of the financial institutions where the Company has deposits. The Company sells some of its products through a network of unaffiliated distributors. The Company also reserves the right to sell directly to the end user to secure the customer’s account. No customer represented more than 10% of total net sales for the years ended December 31, 2016 , 2015 or 2014 . At December 31, 2016 and 2015 , the Company had a trade receivable from one unaffiliated customer comprising 14.5% and 12.5% , respectively, of the aggregate accounts receivable balance. The Company currently purchases finished circuit boards and injection-molded plastic components from suppliers located in the U.S., Mexico and Taiwan. Although the Company currently obtains many of these components from single source suppliers, the Company owns the injection molded component tooling used in their production. As a result, management believes it could obtain alternative suppliers in most cases without incurring significant production delays. The Company also purchases small, machined parts from a vendor in Taiwan, custom cartridge assemblies from a proprietary vendor in the U.S., and electronic components from a variety of foreign and domestic distributors. Management believes that there are readily available alternative suppliers in most cases who can consistently meet the Company's needs for these components. The Company acquires most of its components on a purchase order basis and does not have any significant long-term contracts with suppliers. o. Fair Value of Financial Instruments The Company uses the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: • Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. • Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. • Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect the Company's own assumptions about inputs that market participants would use in pricing an asset or liability. The Company has cash equivalents and investments, which at December 31, 2016 and 2015 , were comprised of money market funds, state and municipal obligations, corporate bonds, and certificates of deposits. See additional disclosure regarding the fair value of the Company’s cash equivalents and investments in Note 2. Included in the balance of other assets as of December 31, 2016 and 2015 was $3.2 million and $2.2 million , respectively, related to corporate-owned life insurance policies which are used to fund the Company’s deferred compensation plan. The Company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. The Company’s financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the balance sheet. p. Segment and Geographic Information The Company is comprised of two reportable segments: the sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the Axon business, focused on devices, wearables, applications, cloud and mobile products (the "Axon" segment). Reportable segments are determined based on discrete financial information reviewed by the Company’s Chief Executive Officer who is the chief operating decision maker for the Company. The Company organizes and reviews operations based on products and services, and currently there are no operating segments that are aggregated. The Company performs an annual analysis of its reportable segments. Additional information related to the Company’s business segments is summarized in Note 16. For the three years ended December 31, 2016 , 2015 and 2014 , net sales by geographic area were as follows (in thousands): Year Ended December 31, 2016 2015 2014 United States $ 218,757 81.6 % $ 161,803 81.8 % $ 132,205 80.4 % Other Countries 49,488 18.4 36,089 18.2 32,320 19.6 Total $ 268,245 100.0 % $ 197,892 100.0 % $ 164,525 100.0 % Sales to customers outside of the U.S. are typically denominated in U.S. dollars and are attributed to each country based on the shipping address of the distributor or customer. For the three years ended December 31, 2016 , 2015 and 2014 , no individual country outside the U.S. represented more than 10% of net sales. Substantially all of the Company’s assets are located in the U.S. q. Stock-Based Compensation The Company calculates the fair value of stock options using the Black-Scholes-Merton option pricing valuation model, which incorporates various assumptions including volatility, expected life and risk-free interest rates. No options were awarded during the years ended December 31, 2016 , 2015 or 2014 . The fair value of restricted stock units is estimated as the closing price of the Company's common stock on the date of grant. The estimated fair value of stock-based compensation awards is amortized to expense on a straight-line basis over the requisite service periods. As stock-based compensation expense recognized is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company’s forfeiture rate was calculated based on its historical experience of awards which ultimately vested. See Note 12 for further disclosure about the Company’s stock-based compensation. r. Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution that would occur if outstanding stock options were exercised utilizing the treasury stock method. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): For the Year Ended December 31, 2016 2015 2014 Numerator for basic and diluted earnings per share: Net income $ 17,297 $ 19,933 $ 19,918 Denominator: Weighted average shares outstanding—basic 52,667 53,548 52,948 Dilutive effect of stock-based awards 869 1,090 1,552 Diluted weighted average shares outstanding 53,536 54,638 54,500 Anti-dilutive stock-based awards excluded 443 198 177 Net income per common share: Basic $ 0.33 $ 0.37 $ 0.38 Diluted $ 0.32 $ 0.36 $ 0.37 s. Recently Issued Accounting Guidance In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 requires entities to recognize revenue through the application of a five-step model, which includes identification of the contract, identification of the performance obligations, determination of the transaction price, allocation of the transaction price to the performance obligations and recognition of revenue as the entity satisfies the performance obligations. Subsequently, the FASB issued the following accounting standard updates related to Topic 606, Revenue Contracts with Customers: • ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) in March 2016. ASU 2016-08 does not change the core principle of revenue recognition in Topic 606 but clarifies the implementation guidance on principal versus agent considerations. • ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing in April 2016. ASU 2016-10 does not change the core principle of revenue recognition in Topic 606 but clarifies the implementation guidance on identifying performance obligations and the licensing • ASUs No. 2016-12 and 2016-20, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. These ASUs do not change the core principle of revenue recognition in Topic 606 but clarifies the implementation guidance on a few narrow areas and adds some practical expedients to the guidance. The amendments are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. During Fiscal 2016, the Company established an internal implementation team and engaged a third-party advisory firm to assist in the implementation of the new standard. The Company is currently finalizing its assessment relative to the adoption of this guidance, and currently does not expect it will have significant impact on its consolidated financial statements. The Company is also evaluating whether to adopt the guidance using the full or modified retrospective basis, and will likely make that determination during the first half of Fiscal 2017. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). The amendments require that an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company adopted thi

Cash, Cash Equivalents and Inve

Cash, Cash Equivalents and Investments	12 Months Ended
	Dec. 31, 2016
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Investments The following tables summarize the Company's cash, cash equivalents, and held-to-maturity investments at December 31 (in thousands): As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 32,802 $ — $ — $ 32,802 $ 32,802 $ — $ — Level 1: Money market funds 7,849 — — 7,849 7,849 — — Corporate bonds 33,379 — (57 ) 33,322 — 33,379 — Subtotal 41,228 — (57 ) 41,171 7,849 33,379 — Level 2: State and municipal obligations 14,477 — (10 ) 14,467 — 14,243 234 Certificates of deposit 793 — — 793 — 793 — Subtotal 15,270 — (10 ) 15,260 — 15,036 234 Total $ 89,300 $ — $ (67 ) $ 89,233 $ 40,651 $ 48,415 $ 234 As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 57,137 $ — $ — $ 57,137 $ 57,137 $ — $ — Level 1: Money market funds 2,389 — — 2,389 2,389 — — Corporate bonds 36,406 — (70 ) 36,336 — 35,677 729 Subtotal 38,795 — (70 ) 38,725 2,389 35,677 729 Level 2: State and municipal obligations 19,002 11 (9 ) 19,004 — 12,000 7,002 Certificates of deposit 3,371 — — 3,371 — 2,577 794 Subtotal 22,373 11 (9 ) 22,375 — 14,577 7,796 Total $ 118,305 $ 11 $ (79 ) $ 118,237 $ 59,526 $ 50,254 $ 8,525 The Company believes the unrealized losses on the Company’s investments are due to interest rate fluctuations. As these investments are either short-term in nature, are expected to be redeemed at par value and/or because the Company has the ability and intent to hold these investments to maturity, the Company does not consider these investments to be other than temporarily impaired at December 31, 2016 . None of Company’s investments have been in an unrealized loss position for more than one year. The following table summarizes the amortized cost and fair value of the short-term and long-term investments held by the Company at December 31, 2016 by contractual maturity (in thousands): Amortized Cost Fair Value Due in less than one year $ 48,415 $ 48,349 Due after one year, through two years 234 233 Due after two years — — Total short-term and long-term investments $ 48,649 $ 48,582

Inventory

Inventory	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory	Inventory Inventories consisted of the following at December 31 (in thousands): 2016 2015 Raw materials $ 18,002 $ 8,853 Finished goods 16,839 6,910 Total inventory $ 34,841 $ 15,763

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consisted of the following at December 31 (in thousands): Estimated Useful Life 2016 2015 Land N/A $ 2,900 $ 2,900 Building and leasehold improvements 3-39 years 15,295 15,246 Production equipment 3-7 years 19,849 18,689 Computer equipment 3-5 years 7,985 8,048 Furniture and office equipment 5-7 years 4,990 4,116 Vehicles 5 years 675 713 Website development costs 3 years 601 601 Capitalized software development costs 3 years 3,695 3,670 Construction-in-process N/A 5,813 3,885 Total cost 61,803 57,868 Less: Accumulated depreciation (37,799 ) (36,020 ) Property and equipment, net $ 24,004 $ 21,848 Depreciation and amortization expense relative to property and equipment, including equipment under capital lease, was $2.5 million , $2.3 million and $4.0 million for the years ended December 31, 2016 , 2015 and 2014 , respectively, of which $0.7 million , $0.7 million and $2.8 million was included in cost of products sold and services delivered for the respective years.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The changes in the carrying amount of goodwill for the year ended December 31, 2016 were as follows (in thousands): Balance, January 1, 2015 $ 9,596 Goodwill acquired 1,615 Purchase accounting adjustments (520 ) Foreign currency translation adjustments (249 ) Balance, December 31, 2016 $ 10,442 Intangible assets (other than goodwill) consisted of the following (in thousands): December 31, 2016 December 31, 2015 Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Amortized: Domain names 5-10 years $ 3,161 $ (125 ) $ 3,036 $ 125 $ (120 ) $ 5 Issued patents 4-15 years 1,942 (780 ) 1,162 1,866 (659 ) 1,207 Issued trademarks 3-11 years 655 (320 ) 335 603 (255 ) 348 Customer relationships 4-8 years 914 (240 ) 674 1,035 (93 ) 942 Non-compete agreements 3-4 years 465 (236 ) 229 464 (164 ) 300 Developed technology 5-7 years 8,661 (824 ) 7,837 3,470 (326 ) 3,144 Total amortized 15,798 (2,525 ) 13,273 7,563 (1,617 ) 5,946 Not amortized: TASER trademark 900 900 900 900 Patents and trademarks pending 1,045 1,045 742 742 Total not amortized 1,945 1,945 1,642 1,642 Total intangible assets $ 17,743 $ (2,525 ) $ 15,218 $ 9,205 $ (1,617 ) $ 7,588 Amortization expense related to intangible assets was $0.9 million , $0.8 million and $0.2 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Estimated amortization for intangible assets with definitive lives for the next five years, and thereafter, is as follows for the years ended December 31 (in thousands): 2017 $ 2,281 2018 2,268 2019 2,145 2020 2,084 2021 2,076 Thereafter 2,419 Total $ 13,273

Other Long-Term Assets

Other Long-Term Assets	12 Months Ended
	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Long-Term Assets	Other Long-Term Assets Other long-term assets consisted of the following at December 31 (in thousands): 2016 2015 Cash surrender value of corporate-owned life insurance policies (Note 1) $ 3,240 $ 2,180 Prepaid commissions (i) 5,302 3,543 Restricted cash (ii) 3,317 — Prepaid expenses, deposits and other (iii) 2,058 246 $ 13,917 $ 5,969 (i) Prepaid commissions represent customer acquisition costs to secure long-term contracts. The Company capitalizes incremental and direct costs related to a specific contract and recognizes expense over the term of the contract. (ii) As of December 31, 2016, restricted cash primarily consisted of $2.7 million of sales proceeds related to a long-term contract with a specific customer. These proceeds are held in escrow until certain billing milestones are achieved, and then specified amounts are transferred to the Company's operating accounts. Restricted also contained $0.6 million related to a performance guarantee related to an international customer sales contract. (iii) Included in long-term assets as of December 31, 2016 was $1.8 million of funds deposited in escrow related to contingent consideration in connection with a business combination (see Note 15). The funds will be held in escrow and released to selling shareholders if certain conditions are subsequently met. If the conditions are not met, the funds will be released back to the Company.

Deferred Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2016
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	Deferred Revenue Deferred revenue consisted of the following at December 31 (in thousands): December 31, 2016 December 31, 2015 Current Long-Term Total Current Long-Term Total Warranty: TASER Weapons $ 9,783 $ 17,319 $ 27,102 $ 7,278 $ 13,982 $ 21,260 Axon 3,979 2,926 6,905 2,332 2,344 4,676 13,762 20,245 34,007 9,610 16,326 25,936 Hardware: TASER Weapons 1,702 4,390 6,092 952 2,459 3,411 Axon 9,850 11,205 21,055 786 7,382 8,168 11,552 15,595 27,147 1,738 9,841 11,579 Axon Services 19,626 4,214 23,840 9,303 4,023 13,326 Other 197 — 197 200 — 200 Total $ 45,137 $ 40,054 $ 85,191 $ 20,851 $ 30,190 $ 51,041 December 31, 2016 December 31, 2015 Current Long-Term Total Current Long-Term Total TASER Weapons and other $ 11,682 $ 21,709 $ 33,391 $ 8,430 $ 16,441 $ 24,871 Axon 33,455 18,345 51,800 12,421 13,749 26,170 Total $ 45,137 $ 40,054 $ 85,191 $ 20,851 $ 30,190 $ 51,041

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consisted of the following at December 31 (in thousands): 2016 2015 Accrued salaries, benefits and bonus $ 6,474 $ 3,637 Accrued professional, consulting and lobbying 3,673 1,098 Accrued warranty expense 780 314 Accrued income and other taxes 4,581 1,215 Other accrued expenses 2,740 2,379 Accrued liabilities $ 18,248 $ 8,643

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies a. Operating and capital lease obligations The Company has entered into operating leases for various office space, storage facilities and equipment. As of December 31, 2016 , the Company's leases are for terms ranging from less than one year to six years. The Company's leases generally contain multi-year renewal options and escalation clauses. Rent expense under all operating leases, including both cancelable and non-cancelable leases, was $1.8 million , $1.0 million and $0.9 million for the years ended December 31, 2016 , 2015 , and 2014 , respectively. Future minimum lease payments under non-cancelable leases at December 31, 2016 , are as follows (in thousands): Operating Capital 2017 $ 1,440 $ 36 2018 1,278 36 2019 646 36 2020 653 33 2021 596 — Thereafter 504 — Total minimum lease payments $ 5,117 141 Less: Amount representing interest (11 ) Capital lease obligation $ 130 b. Purchase commitments The Company routinely enters into cancelable purchase orders with many of its key vendors. Based on the strategic relationships with many of these vendors, the Company’s ability to cancel these purchase orders and maintain a favorable relationship would be limited. As of December 31, 2016 , the Company has approximately $46.0 million of open purchase orders. c. Litigation Product Litigation The Company is currently named as a defendant in eight lawsuits in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CEW was used (or present) by law enforcement officers in connection with arrests or during training exercises. While the facts vary from case to case, the product liability claims are typically based on an alleged product defect resulting in injury or death, usually involving a failure to warn, and the plaintiffs are seeking monetary damages. The information throughout this note is current through the date of these financial statements. As a general rule, it is the Company’s policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to the Company. Also, on occasion, the Company’s insurance carrier has settled such lawsuits over the Company’s objection where the risk is over the Company’s liability insurance deductibles. Due to the confidentiality of the Company's litigation strategy and the confidentiality agreements that are executed in the event of a settlement, the Company does not identify or comment on which specific lawsuits have been settled or the amount of any settlement. In 2009, the Company implemented new risk management strategies, including revisions to product warnings and training to better protect both the Company and its customers from litigation based on ‘failure to warn’ theories – which comprise the vast majority of the cases against the Company. These risk management strategies have been highly effective in reducing the rate and exposure from litigation post-2009. From the third quarter of 2011 through the date of these financial statements, product liability cases have been reduced from 55 active to eight active cases. Management believes that pre-2009 cases have a different risk profile than cases which have occurred since the risk management procedures were introduced in 2009. Therefore, the Company necessarily treats certain pre-2009 cases as exceptions to the Company’s general no settlement policy in order to reduce caseload, legal costs and liability exposure. The Company intends to continue its successful practice of aggressively defending and generally not settling litigation except in very limited and unusual circumstances as described above. With respect to each of the pending lawsuits, the following table lists the name of plaintiff, the date the Company was served with process, the jurisdiction in which the case is pending, the type of claim and the status of the matter. Plaintiff Month Served Jurisdiction Claim Type Status Derbyshire Nov-09 Ontario, Canada Superior Court of Justice Officer Injury Discovery Phase Shymko Dec-10 The Queen's Bench, Winnipeg Centre, Manitoba Wrongful Death Pleading Phase Ramsey Jan-12 12th Judicial Circuit Court, Broward County, FL Wrongful Death Discovery Phase Firman Apr-12 Ontario, Canada Superior Court of Justice Wrongful Death Dismissal Pending Schrock Sep-14 San Bernardino County Superior Court, CA Wrongful Death Motion of Summary Judgment Granted on all claims except negligent design and manufacture, subject to repleading by Plaintiff. Plaintiff filed an amended complaint for negligent design claims as well as a Petition for Writ of Mandate or Prohibition Petition from the Court; which writ was summarily denied. Trial scheduled for August 14, 2017 Bennett Sep-15 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Discovery Phase Suarez Sep-16 US District Court, Southern District of Florida Wrongful Death Pleading Phase Masters Nov-16 US District Court, Western District of Missouri Suspect Injury Pleading Phase There are no product litigation matters in which the Company is involved that are currently on appeal. There were 4 cases that were dismissed or judgment entered during the fourth quarter of 2016 and through the date of these financial statements. Cases that were dismissed or judgment entered in prior fiscal quarters are not included. Plaintiff Month Served Jurisdiction Claim Type Status Doan Apr-10 The Queen's Bench Alberta, Red Deer Judicial Dist. Wrongful Death Dismissed Hernandez/Llach Sep-15 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Dismissed Williams Aug-16 US District Court for the Northern District of Georgia Wrongful Death Dismissed Ramos Dec-16 US District Court for the Northern District of Illinois Conspiracy and negligent spoliation Dismissed The claims, and in some instances the defense, of each of these lawsuits have been submitted to the Company’s insurance carriers that maintained insurance coverage during the applicable periods. The Company continues to maintain product liability insurance coverage with varying limits and deductibles. The following table provides information regarding the Company’s product liability insurance. Remaining insurance coverage is based on information received from the Company’s insurance provider (in millions). Policy Year Policy Start Date Policy End Date Insurance Coverage Deductible Amount Defense Costs Covered Remaining Insurance Coverage Active Cases and Cases on Appeal 2009 12/15/2008 12/15/2009 $ 10.0 $ 1.0 N $ 10.0 Derbyshire 2010 12/15/2009 12/15/2010 10.0 1.0 N 10.0 Shymko 2011 12/15/2010 12/15/2011 10.0 1.0 N 10.0 n/a Jan-Jun 2012 12/15/2011 6/25/2012 7.0 1.0 N 7.0 Ramsey, Firman Jul-Dec 2012 6/25/2012 12/15/2012 12.0 1.0 N 12.0 n/a 2013 12/15/2012 12/15/2013 12.0 1.0 N 12.0 n/a 2014 12/15/2013 12/15/2014 11.0 4.0 N 11.0 Schrock 2015 12/15/2014 12/15/2015 10.0 5.0 N 10.0 Bennett 2016 12/15/2015 12/15/2016 10.0 5.0 N 10.0 Suarez, Masters Other Litigation In November 2015, the Company filed a complaint against Phazzer Electronics Inc. and Sang Min International Co. Ltd. for patent infringement, trademark infringement and false advertising. Defendant Phazzer has filed a motion to dismiss. Phazzer has filed an ex parte review with the USPTO to invalidate the Company’s patent on its data log as well as a cancellation of the Company’s trademark on its cartridge, which cancellation proceeding has been stayed. This litigation is in the motion/discovery phase with a trial date on September 5, 2017. In February 2016, the Company was served with a first amended complaint filed by Digital Ally in the Federal District Court for the District of Kansas alleging patent infringement, commercial bribery, contracts, combinations and conspiracies in restraint of trade and unfair or anti-competitive acts and practices. In March 2016, the Company was served with a second amended complaint with similar allegations. The second amended complaint seeks a judgment of infringement, monetary damages, a permanent injunction, punitive damages and attorneys’ fees and costs. The Company believes the second amended complaint is frivolous and the Company will vigorously defend this litigation. The Company’s motion to dismiss the claims involving commercial bribery, contracts, combinations and conspiracies in restraint of trade and unfair or anti-competitive acts and practices, was granted. The Company has filed four inter parte reviews with the USPTO to invalidate Digital Ally’s patents and also has filed a motion to stay the litigation pending resolution of the inter parte reviews. This litigation is in the discovery phase. In April 2016, the Company was served with a notice of arbitration claim filed by Antoine di Zazzo, the Company’s former distributor in France, for commissions allegedly owed Mr. di Zazzo. The arbitration claim was filed with the International Court of Arbitration of the International Chamber of Commerce in Paris, France, and the amount that is claimed in controversy is approximately $0.6 million . The Company’s records reflect that all commissions that were due Mr. di Zazzo under his contract were paid or offered to him and the Company will vigorously defend this arbitration claim. General From time to time, the Company is notified that it may be a party to a lawsuit or that a claim is being made against it. It is the Company’s policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on the Company. After carefully assessing the claim, and assuming the Company determines that it is not at fault or it disagrees with the damages or relief demanded, the Company vigorously defends any lawsuit filed against the Company. In certain legal matters, the Company records a liability when losses are deemed probable and reasonably estimable. In evaluating matters for accrual and disclosure purposes, the Company takes into consideration factors such as its historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of prevailing, and the severity of any potential loss. The Company reevaluates and updates its accruals as matters progress over time. Based on the Company's assessment of outstanding litigation and claims as of December 31, 2016 , the Company has determined that it is not reasonably possible that these lawsuits will individually, or in the aggregate, materially affect its results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on the Company's operating results, financial condition or cash flows. d. Employment Agreements The Company has employment agreements with certain key executives. The Company may terminate the agreements with or without cause. Should the Company terminate the agreements without cause, or upon a change of control of the Company or death or disability of the employee, the employee, or family of the employee, are entitled to additional compensation. Under these circumstances, these officers and employees would receive cash compensation amounts remaining under their contracts upon termination, which range from approximately $0.7 million to $1.3 million as of December 31, 2016 , depending on the nature of the termination event. In November 2016, the Company announced a transition plan with an executive officer. In connection with the severance agreement, the Company accrued approximately $0.6 million as of December 31, 2016, and will incur approximately $0.9 million in additional severance during the first quarter of 2017. e. Off-Balance Sheet Arrangements Under certain circumstances, the Company uses letters of credit and surety bonds to guarantee its performance under various contracts, principally in connection with the installation and integration of its Axon cameras and related technologies. Certain of the Company's letters of credit contracts and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. The Company expects to fulfill all contractual performance obligations related to outstanding guarantees. At December 31, 2016 , the Company had an outstanding letter of credit of approximately $2.7 million which is expected to expire in May 2017. Additionally, the Company had approximately $5.7 million of outstanding surety bonds at December 31, 2016 , with $0.4 million expiring in 2018, $2.4 million expiring in 2020, and the remaining $2.9 million expiring in 2021.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income before income taxes included the following components for the years ended December 31 (in thousands): 2016 2015 2014 United States $ 38,414 $ 42,761 $ 32,751 Foreign (6,917 ) (7,400 ) (440 ) Total $ 31,497 $ 35,361 $ 32,311 Significant components of the Company’s deferred income tax assets and liabilities are as follows at December 31 (in thousands): 2016 2015 Deferred income tax assets: Net operating loss carryforward $ 2,405 $ 649 Deferred revenue 11,537 6,762 Deferred compensation 1,695 1,252 Inventory reserve 1,126 956 Non-qualified and non-employee stock option expense 4,410 3,393 Capitalized research and development 1,991 3,348 Research and development tax credit carryforward 2,722 2,386 Reserves, accruals, and other 1,239 1,067 Total deferred income tax assets 27,125 19,813 Deferred income tax liabilities: Depreciation (2,364 ) (2,228 ) Amortization (1,473 ) (1,979 ) Other (294 ) (187 ) Total deferred income tax liabilities (4,131 ) (4,394 ) Net deferred income tax assets before valuation allowance 22,994 15,419 Valuation allowance (3,479 ) (1,700 ) Net deferred income tax assets $ 19,515 $ 13,719 For the years ended December 31, 2016 , 2015 and 2014 the provision for income taxes includes $1.4 million , $6.9 million and $8.0 million , respectively, of tax expense resulting from stock-based compensation tax benefits that have been recorded as increases to additional paid-in capital on the consolidated statement of changes in stockholders’ equity. The Company has $1.8 million of state net operating losses ("NOLs") which expire at various dates between 2029 and 2034 . The Company also has Federal NOLs of $0.9 million which expire between 2032 and 2034 , and are subject to limitation under IRC Section 382. The Company has $43,000 of federal research and development ("R&D") credits which expire in 2022 and 2023, and are also subject to limitation under IRC Section 382. The Company has $6.4 million of Arizona R&D credits carrying forward, which expire at various dates between 2018 and 2032 , In Australia, the UK, Canada, and Germany, the Company has $1.5 million , $5.5 million , $0.7 million , and $1.1 million of NOLs, respectively, which expire at various dates or may be carried forward indefinitely. In preparing the Company’s consolidated financial statements, management has assessed the likelihood that deferred income tax assets will be realized from future taxable income. In evaluating the ability to recover its deferred income tax assets, management considers all available evidence, positive and negative; including the Company’s operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred income tax assets will not be realized. Management exercises significant judgment in determining the Company’s provisions for income taxes, its deferred income tax assets and liabilities and its future taxable income for purposes of assessing its ability to utilize any future tax benefit from its deferred income tax assets. Although management believes that its tax estimates are reasonable, the ultimate tax determination involves significant judgments that could become subject to audit by tax authorities in the ordinary course of business. As of each reporting date, management considers new evidence, both positive and negative, that could impact management’s view with regards to future realization of deferred tax assets. As of December 31, 2016 , the Company continues to demonstrate three-year cumulative pre-tax income in the U.S. federal and Arizona tax jurisdictions; however, the Arizona R&D Tax Credits start to expire in 2018 with a significant tranche with a gross value of $1.2 million expiring in 2019. Under the Company’s new structure, it appears that long term investments which impact short term profits will likely result in some of the R&D credits expiring before they are utilized. Therefore, management has concluded that it is more likely than not that a portion of the Company’s U.S. deferred tax assets will not be realized. As of December 31, 2016 , the Company has cumulative losses in Australia, the UK, Canada, and Germany, which limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this evaluation, a full valuation allowance has been recorded for these jurisdictions. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as projections for growth. Significant components of the provision for income taxes are as follows for the years ended December 31 (in thousands) 2016 2015 2014 Current: Federal $ 16,346 $ 13,594 $ 7,793 State 1,534 996 800 Foreign 1,050 — — Total current 18,930 14,590 8,593 Deferred: Federal (4,145 ) 288 2,656 State (977 ) 984 942 Foreign (45 ) (278 ) — Total deferred (5,167 ) 994 3,598 Tax provision recorded as an increase (decrease) in liability for unrecorded tax benefits 437 (156 ) 202 Provision for income taxes $ 14,200 $ 15,428 $ 12,393 A reconciliation of the Company’s effective income tax rate to the federal statutory rate follows for the years ended December 31 (in thousands): 2016 2015 2014 Federal income tax at the statutory rate $ 11,024 $ 12,347 $ 11,236 State income taxes, net of federal benefit 889 1,061 1,433 Difference between statutory and foreign tax rates (i) 1,521 2,442 — Permanent differences (ii) (457 ) (205 ) 98 Research and development (1,928 ) (1,050 ) (452 ) Return to provision adjustment 327 (67 ) 28 Change in liability for unrecognized tax benefits 700 (156 ) 202 Incentive stock option benefit (77 ) (144 ) (616 ) Change in valuation allowance 1,779 1,200 500 Tax effects of intercompany transactions 630 — — Other (208 ) — (36 ) Provision for income taxes $ 14,200 $ 15,428 $ 12,393 Effective tax rate 45.1 % 43.6 % 38.4 % (i) The difference between statutory and foreign tax rates of $1.5 million was largely driven by losses incurred in a foreign entity for which no tax benefit will be realized, partially reduced by a tax benefit for foreign entities for which the statutory tax rate is lower than the U.S. statutory tax rate. (ii) Permanent differences include certain expenses that are not deductible for tax purposes including lobbying fees as well as favorable items including the domestic production activities deduction. The Company has completed research and development tax credit studies which identified approximately $14.1 million in tax credits for federal, Arizona and California income tax purposes related to the 2003 through 2016 tax years. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of $3.9 million as of December 31, 2016 . In addition, management accrued approximately $0.2 million for estimated uncertain tax positions related to certain state income tax liabilities. Should the unrecognized tax benefit of $4.1 million be recognized, the Company’s effective tax rate would be favorably impacted. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying Consolidated Statement of Operations. As of December 31, 2016 and 2015 , respectively, the Company had accrued interest of $98,000 and $55,000 . The following table presents a roll forward of the Company's liability for unrecognized tax benefits, exclusive of accrued interest, as of December 31 (in thousands): 2016 2015 2014 Balance, beginning of period $ 3,396 $ 3,325 $ 3,110 Decrease in previous year tax positions — (389 ) — Increase in current year tax positions 448 270 121 Decrease due to lapse of statute of limitations — (14 ) — Increase related to adjustment of previous estimates of activity 206 204 94 Balance, end of period $ 4,050 $ 3,396 $ 3,325 Federal income tax returns for 2004 through 2016 remain open to examination by the U.S. Internal Revenue Service (the “IRS”), while state and local income tax returns for 2004 through 2016 also remain open to examination by state taxing authorities. The 2004 through 2011 income tax returns are only open to the extent that net operating loss or other tax attributes carrying forward from those years were utilized in 2012 through 2016. The foreign tax returns for 2013 through 2016 also remain open to examination. The Company has not been notified by any major federal, foreign, or state tax jurisdictions that it will be subject to examination. The Company considers the earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and the Company's specific plans for reinvestment of those subsidiary earnings. It is not practicable to estimate the amount of the deferred tax liability, if any, related to investments in those foreign subsidiaries. If the Company decides to repatriate the foreign earnings, it would need to adjust its income tax provision in the period it determined that the earnings will no longer be indefinitely invested outside the United States.

Line of Credit

Line of Credit	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Line of Credit	Line of Credit The Company has a $10.0 million revolving line of credit with a domestic bank. At December 31, 2016 and 2015 , there were no borrowings under the line. Under the terms of the line of credit, available borrowings are reduced by outstanding letters of credit. As of December 31, 2016 , the Company had letters of credit outstanding of approximately $2.7 million under the facility and available borrowing of $7.3 million . The line is secured by substantially all of the assets of the Company, and bears interest at varying rates (currently LIBOR plus 1.5% or Prime less 0.75% ). The line of credit matures on July 31, 2017 , and requires monthly payments of interest only. The Company’s agreement with the bank requires it to comply with certain financial and other covenants including maintenance of a minimum leverage ratio and fixed charge coverage ratio. The leverage ratio (ratio of total liabilities to tangible net worth) can be no greater than 1 :1, and the fixed charge coverage ratio can be no less than 1.25 :1, based upon a trailing twelve -month period. At December 31, 2016 , the Company’s tangible net worth ratio was 1.02 :1 and its fixed charge coverage ratio was 2.30 :1. The Company's violation of the leverage ratio requirement was waived as of December 31, 2016.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity a. Common Stock and Preferred Stock The Company has authorized the issuance of two classes of stock designated as “common stock” and “preferred stock,” each having a par value of $0.00001 per share. The Company is authorized to issue 200 million shares of common stock and 25 million shares of preferred stock. b. Stock Repurchase In February 2016, the Company announced that TASER's Board of Directors authorized a stock repurchase program to acquire up to $50.0 million of the Company’s outstanding common stock subject to stock market conditions and corporate considerations. During the year ended December 31, 2016, the Company purchased, under a Rule 10b5-1 plan, approximately 1.8 million common shares for a total cost of approximately $33.7 million , or a weighted average cost of $18.90 per share. As of December 31, 2016, $16.2 million remains available under the plan for future purchases. The Company suspended its 10b-5 plan, and any future purchases will be discretionary. In May 2014, the Company announced that TASER's Board of Directors authorized a stock repurchase program to acquire up to $30.0 million of the Company’s outstanding common stock subject to stock market conditions and corporate considerations. Under this program, which was completed in the third quarter of 2015, the Company purchased approximately 2.0 million common shares for a total cost of approximately $30.0 million , or a weighted average cost, including commissions of $14.85 per share. As of December 31, 2015, no amounts remained available under the plan for future purchases. c. Stock-based Compensation Plans The Company has historically utilized stock-based compensation, consisting of restricted stock units (“RSUs”) and stock options, for key employees and non-employee directors as a means of attracting and retaining quality personnel. Service-based grants generally have a vesting period of 3 to 5 years and a contractual maturity of ten years . Performance-based grants generally have vesting periods ranging from 1 to 5 years and a contractual maturity of ten years . On February 26, 2016, the Company’s Board of Directors approved the 2016 Stock Incentive Plan (the “2016 Plan") which was subsequently approved by stockholders at the Annual Meeting of Stockholders on May 26, 2016. Under the 2016 Plan, the Company reserved for future grants: (i) 2.0 million shares of common stock, plus (ii) the number of shares of common stock that were authorized but unissued under the Company’s 2013 Stock Incentive Plan (the “2013 Plan”) as of the effective date of the 2016 Plan, and (iii) the number of shares of stock that have been granted under the 2013 Plan or the 2009 Stock Incentive Plan that either terminate, expire or lapse for any reason after the effective date of the 2016 Plan. As of December 31, 2016 , approximately 2.7 million shares remain available for future grants. Shares issued upon exercise of stock awards from these plans have historically been issued from the Company’s authorized unissued shares. d. Performance-based stock awards The Company has issued performance-based stock options and performance-based RSUs, the vesting of which is generally contingent upon the achievement of certain performance criteria related to the operating performance of the Company as well as successful and timely development and market acceptance of future product introductions. In addition, certain of the performance RSUs have additional service requirements subsequent to the achievement of the performance criteria. Compensation expense is recognized over the implicit service period (the longer of the period the performance condition is expected to be achieved or the required service period) based on management’s estimate of the probability of the performance criteria being satisfied, adjusted at each balance sheet date. e. Restricted Stock Units The following table summarizes RSU activity for the years ended December 31 (number of units and aggregate intrinsic value in thousands): 2016 2015 2014 Number of Units Weighted Average Grant-Date Fair Value Number of Units Weighted Average Grant-Date Fair Value Number of Units Weighted Average Grant-Date Fair Value Units outstanding, beginning of year 1,139 $ 19.30 1,226 $ 13.23 1,279 $ 9.67 Granted 718 19.75 516 26.18 554 16.98 Released (414 ) 15.91 (488 ) 11.82 (433 ) 7.61 Forfeited (113 ) 21.65 (115 ) 16.72 (174 ) 13.08 Units outstanding, end of year 1,330 20.40 1,139 19.30 1,226 13.23 Aggregate intrinsic value at year end (in thousands) $ 32,239 Aggregate intrinsic value represents the Company’s closing stock price on the last trading day of the period, which was $24.24 per share at December 30, 2016 , multiplied by the number of restricted stock units. The fair value as of the respective vesting dates of RSUs that vested during the year ended December 31, 2016 was $8.4 million . Certain RSUs that vested in 2016 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld during 2016 were 88,289 and had a value of approximately $1.8 million on their respective vesting dates as determined by the Company’s closing stock price. Payments for the employees’ tax obligations are reflected as a financing activity within the statement of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the amount of shares that would have otherwise been issued as a result of the vesting. In 2016 , 2015 and 2014 , the Company granted approximately 79,000 , 49,000 and 140,000 performance-based RSUs, respectively (included in the table above). Certain of the performance-based RSUs outstanding as of December 31, 2016 can vest with a range of shares earned being between 0% and 200% of the targeted shares granted, depending on the final achievement of pre-determined performance criteria achieved as of the measurement date. As of December 31, 2016 , the performance criteria had been met for 0.1 million of the 0.2 million performance-based RSUs outstanding. The Company recognized $2.1 million , $1.5 million and $1.0 million of compensation expense related to performance-based RSUs during the years ended December 2016 , 2015 and 2014 , respectively. f. Stock Option Activity The following table summarizes stock option activity for the years ended December 31 (number of options in thousands): 2016 2015 2014 Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price Options outstanding, beginning of year 1,103 $ 5.37 1,641 $ 5.26 3,366 $ 6.15 Granted — — — — — — Exercised (95 ) 5.02 (525 ) 4.95 (1,644 ) 6.69 Expired / terminated — — (13 ) 7.27 (81 ) 16.59 Options outstanding, end of year 1,008 5.40 1,103 5.37 1,641 5.26 Options exercisable, end of year 977 5.42 1,072 5.39 1,606 5.27 Options expected to vest, end of year 25 4.75 No stock options were granted in 2016 , 2015 or 2014 . Total intrinsic value of options exercised was $2.0 million , $13.6 million and $20.2 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. The intrinsic value for options exercised was calculated as the difference between the exercise price of the underlying stock option awards and the market price of the Company’s common stock on the date of exercise. The following table summarizes information about stock options outstanding and exercisable as of December 31, 2016 (number of options in thousands): Options Outstanding Options Exercisable Range of Exercise Price Number of Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Number of Options Exercisable Weighted Average Price Weighted Average Remaining Contractual Life (Years) $4.00 - $5.00 722 $ 4.65 2.66 691 $ 4.64 2.69 $5.01 - $7.00 112 5.57 1.70 112 5.57 1.70 $7.01 - $10.00 106 7.25 1.19 106 7.25 1.19 $10.01 - $16.23 68 10.30 0.40 68 10.30 0.40 $4.00 - $16.23 1,008 5.40 2.25 977 5.42 2.25 The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2016 was $19.0 million and $18.4 million , respectively. Aggregate intrinsic value represents the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock of $24.24 on December 30, 2016 . At December 31, 2016 , the Company had 30,600 unvested options outstanding with a weighted average exercise price of $4.75 per share, weighted average grant-date fair value of $2.58 per share and weighted average remaining contractual life of 2.0 years . The aggregate intrinsic value of unvested options at December 31, 2016 was $0.6 million . The Company granted approximately 1.0 million performance-based stock options (included in the table above) from 2008 through 2011. As of December 31, 2016 , approximately 0.2 million performance-based stock options are outstanding, of which approximately 30,600 are unvested and 25,000 are expected to vest. The aggregate grant-date fair value of the 0.2 million performance-based stock options vested and expected to vest as of December 31, 2016 was approximately $0.6 million . The Company recognized no stock-based compensation expense related to performance-based stock options during the year ended December 31, 2016, $0.1 million during the year ended December 31, 2015, and no expense during the year ended December 31, 2014. g. Stock-based Compensation Expense The Company accounts for stock-based compensation using the fair-value method. Reported stock-based compensation was classified as follows for the years ended December 31 (in thousands): 2016 2015 2014 Cost of products sold and services delivered $ 342 $ 402 $ 204 Sales, general and administrative expenses 5,707 4,285 3,555 Research and development expenses 3,320 2,576 1,820 Total stock-based compensation $ 9,369 $ 7,263 $ 5,579 There was no stock-based compensation expense recognized in the consolidate statements of operations for the year ended December 31, 2016 . Total stock-based compensation expense for the years ended December 31, 2015 and 2014 includes $54,000 and $28,000 , respectively, related to ISOs for which no tax benefit is recognized. The Company recorded a tax benefit in 2016 , 2015 , and 2014 of $0.2 million , $0.2 million , and $0.7 million , respectively, to offset taxes payable related to the non-qualified disposition of ISOs exercised and sold. For the years ended December 31, 2016 , 2015 and 2014 the provision for income taxes included $1.4 million , $6.9 million and $8.0 million , respectively, of tax expense resulting from the fact that stock-based compensation tax benefits have been recorded as increases to additional paid-in capital on the consolidated statements of changes in stockholders' equity. The total future tax benefits related to non-qualified and restricted stock units was $4.4 million and $3.4 million as of December 31, 2016 and 2015 , respectively. As of December 31, 2016 , there was $20.2 million in unrecognized compensation costs related to RSUs under the Company's stock plans. The Company expects to recognize the cost related to the RSUs over a weighted average period of 2.71 years .

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company engages Dr. Mark Kroll, a member of the Board of Directors, to provide consulting services. The expenses related to these services were approximately $0.2 million for each of the years ended December 31, 2016 , 2015 and 2014 . At December 31, 2016 and 2015 , the Company had accrued liabilities of approximately $12,000 and $31,000 , respectively, related to these services. The Company subscribes to a mobile collaboration software suite co-founded and managed by Bret Taylor, a member of the Company's Board of Directors. The cost to license this software is approximately $0.1 million per year, and as of December 31, 2016 and 2015 the Company had $50,500 and $36,000 , respectively, of prepaid costs related to the license subscription.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Plans The Company has a defined contribution profit sharing 401 (k) plan for eligible employees, which is qualified under Sections 401 (a) and 401 (k) of the Internal Revenue Code of 1986, as amended. Employees are entitled to make tax-deferred contributions of up to the maximum allowed by law of their eligible compensation. Contributions to the plans are made by both the employee and the Company. Company contributions are based on the level of employee contributions and are immediately vested. The Company’s matching contributions to the plan for the years ended December 31, 2016 , 2015 and 2014 , were approximately $1.6 million , $1.2 million and $0.9 million , respectively. The Company also has a non-qualified deferred compensation plan for certain executives, key employees and non-employee directors through which participants may elect to postpone the receipt and taxation of a portion of their compensation, including stock-based compensation, received from the Company. The non-qualified deferred compensation plan allows eligible participants to defer up to 80% of their base salary and up to 100% of other types of compensation. The plan also allows for (i) matching and discretionary employer contributions and (ii) the deferral of vested RSU awards. Employee deferrals are deemed 100% vested upon contribution. Distributions from the plan are made upon retirement, death, separation of service, specified date or upon the occurrence of an unforeseeable emergency. Distributions can be paid in a variety of forms from lump sum to installments over a period of years. Participants in the plan are entitled to select from a wide variety of investments available under the plan and are allocated gains or losses based upon the performance of the investments selected by the participant. All gains or losses are allocated fully to plan participants and the Company does not guarantee a rate of return on deferred balances. Assets related to this plan consist of corporate-owned life insurance contracts and are included in other assets in the consolidated balance sheets. Participants have no rights or claims with respect to any plan assets and any such assets are subject to the claims of the Company’s general creditors. Subsequent to December 31, 2016 , the Company made contributions to the non-qualified deferred compensation plan related to the year ended December 31, 2016 of approximately $32,000 . Future matching or profit sharing contributions to the plans are at the Company’s sole discretion.

Business Acquisitions

Business Acquisitions	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Business Acquisitions	Business Acquisitions MediaSolv Solutions Corporation On May 5, 2015, the Company acquired all of the outstanding capital stock of MediaSolv Solutions Corporation, a Delaware corporation, for a total purchase price of $8.8 million , net of $0.1 million of cash acquired. MediaSolv primarily provides solutions for interview room video, closed-circuit television ("CCTV") and on-premise digital evidence management. These products connect with the Company's Axon on-officer cameras and, in some cases, its Evidence.com cloud platform. The Company believes the acquisition will continue to allow the Company to leverage MediaSolv’s existing network and relationships to further strengthen its position in the market. The purchase price consisted primarily of cash, net of cash acquired and working capital adjustments, $7.8 million and contingent consideration of $1.0 million representing potential earn-outs to former stockholders based on predetermined future financial metrics. The Company also agreed to additional earn-out provisions and compensation adjustments totaling approximately $4.0 million based, in part, on predefined future financial metrics. The additional earn-outs were not included as part of the purchase price and will be expensed as compensation in the period earned. During the first quarter of 2016, the $1.0 million of earn-outs to former stockholders were earned in full and were paid during the second quarter of 2016. During the years ended December 31, 2016 and 2015, the Company recorded an additional $1.5 million and $0.2 million , respectively, of earn-outs that were recorded as commission expense, and as of December 31, 2016, $0.2 million of earn-outs were recorded as accrued liabilities within the accompanying consolidated financial statements. The major classes of assets and liabilities to which the Company allocated the purchase price was as follows (in thousands): Accounts receivable and other current assets $ 590 Inventory 35 Property and equipment 53 Intangible assets 4,145 Goodwill 5,496 Accounts payable and accrued liabilities (697 ) Deferred revenue (111 ) Deferred income tax liabilities, net (688 ) Total purchase price $ 8,823 The Company has assigned the goodwill to the Axon segment. Other identifiable definite lived intangible assets were assigned a total weighted average amortization period of 6.5 years. MediaSolv has been included in the Company's consolidated results of operations subsequent to the acquisition date. Pro forma results of operations for MediaSolv have not been presented because they are not material to the consolidated results of operations. In connection with the acquisition, the Company incurred and expensed costs of approximately $0.2 million , which included legal, accounting and other third-party expenses related to the transaction. Tactical Safety Responses Limited On July 16, 2015, TASER International B.V., a wholly owned subsidiary of the Company, acquired all of the outstanding capital stock of Tactical Safety Responses Limited ("TSR"), a United Kingdom ("UK") corporation. TSR is the Company's licensed distributor of TASER CEWs and Axon cameras and related accessories in the UK. The acquisition is intended to help expand the Company's growth across the UK by growing its in-country sales and support team. The total purchase price was $3.3 million consisting of $4.0 million cash at close, net of $0.7 million of cash acquired. The Company also agreed to additional amounts in the form of earn-outs, subject to the achievement of predefined performance metrics. The earn-outs were not included as part of the purchase price and will be expensed as compensation in the period earned. During the year ended December 31, 2016, $0.1 million was recorded as commissions expense under these earn-out provisions. No such expense was recorded during 2015. The major classes of assets and liabilities to which the Company allocated the purchase price was as follows (in thousands): Accounts receivable $ 726 Inventory 497 Property and equipment 583 Other Assets 20 Intangible assets 881 Goodwill 1,441 Accounts payable and accrued liabilities (207 ) Notes payable (169 ) Income tax liabilities (438 ) Total purchase price $ 3,334 The Company has assigned the goodwill equally between the TASER Weapons and Axon segments. Other identifiable definite lived intangible assets were assigned a total weighted average amortization period of 7.0 years. TSR has been included in the Company's consolidated results of operations subsequent to the acquisition date. Pro forma results of operations for TSR have not been presented because they are not material to the consolidated results of operations. In connection with the acquisition, the Company incurred and expensed costs of approximately $0.1 million , which included legal, accounting and other third-party expenses related to the transaction. Axon Artificial Intelligence On December 30, 2016, the Company acquired certain intellectual property from Fossil Group, Inc. and Fossil Vietnam, Limited Liability Company. This transaction, which was accounted for as a business combination under ASC 805, was part of the Company's efforts to expand on the Axon platform by transforming workflows using computer vision and natural language with machine learning techniques in order to analyze data and multimedia captured throughout the course of policing. Additionally, as part of the acquisition, a team of seven researchers and software engineers joined the Company, and will part of the newly established Axon Artificial Intelligence team. The purchase price, totaling approximately $6.8 million , consisted of $3.5 million cash at close, and up to an additional $3.3 million of consideration contingent upon the satisfaction of certain conditions. The Company's purchase price allocation is preliminary and subject to revision as more detailed analyses are completed and additional information about fair value of assets become available. The major classes of assets and liabilities to which the Company has allocated the purchase price, on a preliminary basis, were as follows (in thousands): Developed technology $ 5,210 Goodwill 1,615 Total purchase price $ 6,825 The Company assigned the goodwill to the Axon segment. The acquired developed technology was assigned an amortization period of 5.0 years. Costs related to the acquisition were expensed as incurred and were considered insignificant.

Segment Data

Segment Data	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segment Data	Segment Data The Company’s operations are comprised of two reportable segments: the sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the Axon business, focused on devices, wearables, applications, cloud and mobile products (the "Axon" segment). Within the Axon segment, the Company includes only revenues and costs attributable to that segment which include: costs of sales for both products and services, direct labor, selling expense for the sales team, product management and marketing expenses, trade shows and related expenses, finance and accounting expenses, and research and development for products included, or to be included, within the Axon segment. All other costs are included in the TASER Weapons segment. The chief operating decision maker does not review assets by segment as part of the financial information provided; therefore, only limited asset information is provided in the following tables. Information relative to the Company’s reportable segments was as follows (in thousands): For the year ended December 31, 2016 TASER Weapons Axon Total Product sales $ 202,644 $ 35,929 $ 238,573 Service revenue — 29,672 29,672 Net sales 202,644 65,601 268,245 Cost of products sold 61,930 29,606 91,536 Cost of services delivered — 6,173 6,173 Gross margin 140,714 29,822 170,536 Sales, general and administrative 63,617 44,459 108,076 Research and development 5,887 24,722 30,609 Income (loss) from operations $ 71,210 $ (39,359 ) $ 31,851 Purchase of property and equipment $ 4,129 $ 828 $ 4,957 Purchase of intangible assets 262 3,233 3,495 Purchase of intangible assets in connection with business acquisitions — 6,825 6,825 Depreciation and amortization 2,207 1,451 3,658 For the year ended December 31, 2015 TASER Axon Total Product sales $ 162,375 $ 22,855 $ 185,230 Service revenue — 12,662 12,662 Net sales 162,375 35,517 197,892 Cost of products sold 48,821 16,201 65,022 Cost of services delivered — 4,223 4,223 Gross margin 113,554 15,093 128,647 Sales, general and administrative 47,640 22,058 69,698 Research and development 4,470 19,144 23,614 Income (loss) from operations $ 61,444 $ (26,109 ) $ 35,335 Purchase of property and equipment $ 4,159 $ 1,844 $ 6,003 Purchase of intangible assets 277 224 501 Purchase of property and equipment and intangible assets in connection with business acquisitions 1,453 11,146 12,599 Depreciation and amortization 2,311 980 3,291 For the year ended December 31, 2014 TASER Axon Total Product sales $ 145,613 $ 14,700 $ 160,313 Service revenue — 4,212 4,212 Net sales 145,613 18,912 164,525 Cost of products sold 47,680 13,233 60,913 Cost of services delivered — 2,064 2,064 Gross margin 97,933 3,615 101,548 Sales, general and administrative 42,989 11,169 54,158 Research and development 3,872 11,013 14,885 Income (loss) from operations $ 51,072 $ (18,567 ) $ 32,505 Purchase of property and equipment $ 2,233 $ 272 $ 2,505 Purchase of intangible assets 180 3 183 Depreciation and amortization 3,936 381 4,317

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (unaudited)	Selected Quarterly Financial Data (unaudited) Selected quarterly financial data for years ended December 31, 2016 and 2015 follows (in thousands, except per share data): Quarter Ended March 31, June 30, September 30, December 31, 2016 2016 2016 2016 Net sales $ 55,530 $ 58,756 $ 71,882 $ 82,077 Gross margin 36,902 37,299 46,565 49,770 Net income 3,463 3,650 3,843 6,341 Earnings per share (1) : Basic $ 0.06 $ 0.07 $ 0.07 $ 0.12 Diluted $ 0.06 $ 0.07 $ 0.07 $ 0.12 Quarter Ended March 31, June 30, September 30, December 31, 2015 2015 2015 2015 Net sales $ 44,762 $ 46,713 $ 50,376 $ 56,041 Gross margin 29,868 30,723 31,068 36,988 Net income 7,205 6,103 1,521 5,104 Earnings per share (1) : Basic $ 0.14 $ 0.11 $ 0.03 $ 0.10 Diluted $ 0.13 $ 0.11 $ 0.03 $ 0.09 (1) Basic and diluted earnings per share are computed independently for each of the quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted earnings per share.

Supplemental Disclosure to Cash

Supplemental Disclosure to Cash Flows	12 Months Ended
	Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure to Cash Flows	Supplemental Disclosure to Cash Flows Supplemental non-cash and other cash flow information were as follows for the years ended December 31 (in thousands): 2016 2015 2014 Cash paid for income taxes, net of refunds $ 14,048 $ 6,759 $ 386 Non-cash transactions: Contingent consideration related to business combinations $ 3,325 $ 952 $ — Property and equipment purchases in accounts payable 82 315 270 Purchase of assets under capital lease obligations 134 — —

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On February 9, 2017, the Company acquired all of the outstanding capital stock of Dextro, Inc. ("Dextro"). Dextro's products aim to make videos discoverable and searchable using machine learning further consisting of developed algorithms that can analyze the audiovisual contents of video footage in real time in order to provide meaningful data to end users. These capabilities are intended to expand the Axon platform and the newly developed Axon Artificial Intelligence team. The purchase price consisted of $7.1 million cash, including $1.1 million in the form of earn-outs, subject to the achievement of predefined performance metrics. The acquisition will be accounted for in the first quarter of Fiscal 2017 using the acquisition method in accordance with ASC 805, Business Combinations. Accordingly, the identifiable assets acquired and liabilities assumed will be measured at their acquisition-date fair value. Operating results will be included in the Company’s consolidated financial statements from the effective date of the acquisition.

Schedule II- Valuation and Qual

Schedule II- Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2016
Valuation and Qualifying Accounts [Abstract]
Schedule II- Valuation and Qualifying Accounts	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS Description Balance at Beginning of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End of Period Allowance for doubtful accounts: Year ended December 31, 2016 $ 322 $ 205 $ — $ (84 ) $ 443 Year ended December 31, 2015 251 86 — (15 ) 322 Year ended December 31, 2014 200 142 — (91 ) 251 Warranty reserve: Year ended December 31, 2016 $ 314 $ 621 $ — $ (155 ) $ 780 Year ended December 31, 2015 675 (62 ) — (299 ) 314 Year ended December 31, 2014 955 396 — (676 ) 675

Organization and Summary of S27

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions in these consolidated financial statements include: • product warranty reserves, • inventory valuation, • revenue recognition allocated in multiple-deliverable contracts or arrangements, • valuation of goodwill, intangibles and long-lived assets, • recognition, measurement and valuation of current and deferred income taxes, • recognition and measurement of contingencies and accrued litigation expense. and • fair value of stock awards issued, the estimated vesting period for performance-based stock awards and forfeiture rates, Actual results could differ materially from those estimates.
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Investments Cash, cash equivalents and investments include cash, money market funds, certificates of deposit, state and municipal obligations and corporate bonds. The Company places its cash and cash equivalents with high quality financial institutions. Although the Company deposits its cash with multiple financial institutions, its deposits, at times, may exceed federally insured limits. Cash and cash equivalents include funds on hand and highly liquid investments purchased with initial maturity of three months or less. Short-term investments include securities with an expected maturity date within one year of the balance sheet date that do not meet the definition of a cash equivalent, and long-term investments are securities with an expected maturity date greater than one year. Based on management’s intent and ability, the Company’s investments are classified as held to maturity investments and are recorded at amortized cost. Held-to-maturity investments are reviewed quarterly for impairment to determine if other-than-temporary declines in the carrying value have occurred for any individual investment. Other-than-temporary declines in the value of held-to-maturity investments are recorded as expense in the period the determination is made.
Inventory	Inventory Inventories are stated at the lower of cost or market. Cost is determined using the weighted average cost of raw materials which approximates the first-in, first-out (“FIFO”) method and includes allocations of manufacturing labor and overhead. Provisions are made to reduce potentially excess, obsolete or slow-moving inventories to their net realizable value. These provisions are based on management’s best estimate after considering historical demand, projected future demand, inventory purchase commitments, industry and market trends and conditions and other factors. Management evaluates inventory costs for abnormal costs due to excess production capacity and treats such costs as period costs.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. Additions and improvements are capitalized, while ordinary maintenance and repair expenditures are charged to expense as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets.
Software Development Costs	Software Development Costs The Company expenses software development costs, including costs to develop software products or the software component of products to be marketed to external users, before technological feasibility of such products is reached. The Company has determined that technological feasibility is reached shortly before the release of those products and as a result, the development costs incurred after the establishment of technological feasibility and before the release of those products are not material. Software development costs also include costs to develop software programs to be used solely to meet the Company's internal needs and cloud-based applications used to deliver its services. The Company capitalizes development costs related to these software applications once the preliminary project stage is complete and it is probable that the project will be completed and the software will be used to perform the intended function. Additionally, the Company capitalizes qualifying costs incurred for upgrades and enhancements to existing software that result in additional functionality. Costs related to preliminary project planning activities, post-implementation activities, maintenance and minor modifications are expensed as incurred. Internal-use software is amortized on a straight line basis over its estimated useful life. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.
Valuation of Goodwill, Intangibles and Long-lived Assets	Valuation of Goodwill, Intangibles and Long-lived Assets The Company does not amortize goodwill and intangible assets with indefinite useful lives, rather such assets are required to be tested for impairment at least annually during the fourth quarter or sooner whenever events or changes in circumstances indicate that the assets may be impaired. Finite-lived intangible assets and other long-lived assets are amortized over their useful lives. Management evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and intangible assets may warrant revision or that the remaining balance of these assets, including intangible assets with indefinite lives, may not be recoverable. Circumstances that might indicate long-lived assets might not be recoverable could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way the Company's products are branded and marketed. When performing a review for recoverability, management estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows.
Customer Deposits	Customer Deposits The Company requires deposits in advance of shipment for certain customer sales orders. Customer deposits are recorded as a current liability in the accompanying consolidated balance sheets.
Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable	Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable The Company derives revenue from two primary sources: (1) the sale of physical products, including CEWs, Axon cameras, corresponding extended warranties, and related accessories such as Axon Docks, cartridges and batteries, among others, and (2) subscription to the Company's Evidence.com software as a service ("SaaS") (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, the Company also recognizes training and other professional services revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Contractual arrangements may contain explicit customer acceptance provisions, and under such arrangements, the Company defers recognition of revenue until formal customer acceptance is received. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract. Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price or third-party evidence of the selling prices if vendor-specific objective evidence of selling prices does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price. The majority of the Company’s allocations of arrangement consideration under multiple element arrangements are performed using vendor-specific objective evidence by utilizing prices charged to customers for deliverables when sold separately. The Company’s multiple element arrangements may include future CEWs and/or Axon devices to be delivered at defined points within a multi-year contract, and in those arrangements, the Company allocates total arrangement consideration over the life of the multi-year contract to future deliverables using management’s best estimate of selling price. The Company has not utilized third-party evidence of selling price. The Company offers the right to purchase extended warranties that include additional services and coverage beyond the standard limited warranty for certain products. Revenue for extended warranty purchases is deferred at the time of sale and recognized over the warranty period commencing on the date of sale. Extended warranties range from one to five years. Evidence.com and Axon cameras and related accessories have stand-alone value to the customer and are sometimes sold separately, but in most instances are sold together. In these instances, customers typically purchase and pay for the equipment and one year of Evidence.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. Generally, the Company recognizes revenue for the Axon equipment at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for Evidence.com is deferred at the time of the sale and recognized over the service period. At times the Company subsidizes the cost of Axon devices provided to customers to secure long-term Evidence.com service contracts. In such circumstances, revenue related to the Axon devices recognized at the time of delivery is limited to the amount collected from the customer that is not contingent upon the delivery of future Evidence.com services. The Company recognizes the remaining allocated revenue related to subsidized Axon devices over the remaining period it provides the contracted Evidence.com services. In 2012, the Company introduced a program, the TASER Assurance Program (“TAP”) whereby a customer purchasing a product and joining the program will have the right to trade-in the original product for a new product of the same or like model in the future. Upon joining TAP, customers also receive an extended warranty for the initial products purchased and spare inventory. Under this program the customer generally pays additional annual installments over the contract period, generally three to five years. The Company records consideration received related to the future product purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the new product is delivered. Consideration related to future product purchases is determined at the inception of the arrangement using management’s best estimate of selling price. Management’s estimate is principally based on the current selling price for such products, with due evaluation of the impact of any expected product and pricing changes, which have historically had an immaterial influence on management’s best estimate of selling price. In 2015, The Company introduced the Officer Safety Plan (“OSP”), whereby a customer typically enters into a five year Evidence.com subscription that includes all of its standard advanced features along with unlimited storage. The OSP also includes a service plan that includes upgrades of (i) the Axon devices every 2.5 years and (ii) a TASER CEW at any point within the contract period. Upon entering into the OSP, customers also receive extended warranties on the Axon and CEW devices over the five -year contract periods as well as spare inventory units. Under this program the customer generally makes an initial purchase of Axon cameras and related accessories, and CEWs at inception and pays the first of its annual installments for services and future hardware deliverables over the contract period. The Company records consideration received related to the future purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the products or services are delivered. In 2016, the Company introduced the TASER 60 Plan ("TASER 60") whereby a customer typically enters into a five year CEW installment purchase arrangement. The TASER 60 plan also includes extended warranties on the CEW devices upon delivery covering the contract periods as well as on-site spares, holsters and cartridges. Generally, the Company recognizes revenue for the amount allocated to the CEW at the time of sale for the amount of the customer receivable, net of imputed interest, and the amount allocated to the extended warranty is recognized over five years. Sales tax collected on sales is netted against government remittances and thus, recorded on a net basis. Training revenue is recorded as the service is provided. Deferred revenue consists of payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. Generally, customers are billed in annual installments. See Note 7 for further disclosures about of the Company’s deferred revenue. Sales are typically made on credit and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for estimated potential losses. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents management’s best estimate and is based on their judgment after considering a number of factors, including third-party credit reports, actual payment history, cash discounts, customer-specific financial information and broader market and economic trends and conditions.
Cost of Products Sold and Services Provided	Cost of Products Sold and Services Provided Cost of products sold represents manufacturing costs, consisting of materials, labor and overhead related to finished goods and components. Shipping costs incurred related to product delivery are also included in cost of products sold. Cost of services delivered includes third-party cloud services, and software maintenance and support costs, including personnel costs, associated with supporting Evidence.com.
Advertising Costs	Advertising Costs The Company expenses advertising costs in the period in which they are incurred. The Company incurred advertising costs of $0.4 million , $0.6 million and $0.3 million in the years ended December 31, 2016 , 2015 and 2014 , respectively. Advertising costs are included in sales, general and administrative expenses in the accompanying statements of operations.
Standard Warranties	Standard Warranties The Company warranties its CEWs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to returns and warranty costs on a quarterly basis and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure that could result in larger than anticipated returns from customers. The accrued warranty liability expense is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred. The reserve for warranty returns is included in accrued liabilities on the accompanying consolidated balance sheets.
Research and Development Expenses	Research and Development Expenses The Company expenses as incurred research and development costs that do not meet the qualifications to be capitalized.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in future years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced through the establishment of a valuation allowance if, based upon available evidence, it is determined that it is more likely than not that the deferred tax assets will not be realized. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. Management also assesses whether uncertain tax positions, as filed, could result in the recognition of a liability for possible interest and penalties. The Company’s policy is to include interest and penalties related to unrecognized tax benefits as a component of income tax expense.
Concentration of Credit Risk and Major Customers / Suppliers	Concentration of Credit Risk and Major Customers / Suppliers Financial instruments that potentially subject the Company to concentrations of credit risk consist of accounts and notes receivable and cash. Sales are typically made on credit and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for estimated losses. Uncollectible accounts are written off when deemed uncollectible, and accounts receivable are presented net of an allowance for doubtful accounts, which totaled $0.4 million and $0.3 million as of December 31, 2016 and 2015 , respectively. Historically, the Company has experienced a low level of write-offs related to doubtful accounts. The Company maintains the majority of its cash and cash equivalents accounts at five depository institutions. As of December 31, 2016 , the aggregate balances in such accounts were $33.2 million . The Company’s balances with these institutions regularly exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits for domestic deposits and various deposit insurance programs covering our deposits in the Netherlands, the United Kingdom, Germany and Australia. To manage the related credit exposure, management continually monitors the creditworthiness of the financial institutions where the Company has deposits. The Company sells some of its products through a network of unaffiliated distributors. The Company also reserves the right to sell directly to the end user to secure the customer’s account. No customer represented more than 10% of total net sales for the years ended December 31, 2016 , 2015 or 2014 . At December 31, 2016 and 2015 , the Company had a trade receivable from one unaffiliated customer comprising 14.5% and 12.5% , respectively, of the aggregate accounts receivable balance. The Company currently purchases finished circuit boards and injection-molded plastic components from suppliers located in the U.S., Mexico and Taiwan. Although the Company currently obtains many of these components from single source suppliers, the Company owns the injection molded component tooling used in their production. As a result, management believes it could obtain alternative suppliers in most cases without incurring significant production delays. The Company also purchases small, machined parts from a vendor in Taiwan, custom cartridge assemblies from a proprietary vendor in the U.S., and electronic components from a variety of foreign and domestic distributors. Management believes that there are readily available alternative suppliers in most cases who can consistently meet the Company's needs for these components. The Company acquires most of its components on a purchase order basis and does not have any significant long-term contracts with suppliers.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company uses the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: • Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. • Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. • Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect the Company's own assumptions about inputs that market participants would use in pricing an asset or liability. The Company has cash equivalents and investments, which at December 31, 2016 and 2015 , were comprised of money market funds, state and municipal obligations, corporate bonds, and certificates of deposits. See additional disclosure regarding the fair value of the Company’s cash equivalents and investments in Note 2. Included in the balance of other assets as of December 31, 2016 and 2015 was $3.2 million and $2.2 million , respectively, related to corporate-owned life insurance policies which are used to fund the Company’s deferred compensation plan. The Company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. The Company’s financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the balance sheet.
Segment and Geographic Information	Segment and Geographic Information The Company is comprised of two reportable segments: the sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the Axon business, focused on devices, wearables, applications, cloud and mobile products (the "Axon" segment). Reportable segments are determined based on discrete financial information reviewed by the Company’s Chief Executive Officer who is the chief operating decision maker for the Company. The Company organizes and reviews operations based on products and services, and currently there are no operating segments that are aggregated. The Company performs an annual analysis of its reportable segments. Additional information related to the Company’s business segments is summarized in Note 16.
Sales to Customers Outside of the U.S.	Sales to customers outside of the U.S. are typically denominated in U.S. dollars and are attributed to each country based on the shipping address of the distributor or customer.
Stock-Based Compensation	Stock-Based Compensation The Company calculates the fair value of stock options using the Black-Scholes-Merton option pricing valuation model, which incorporates various assumptions including volatility, expected life and risk-free interest rates. No options were awarded during the years ended December 31, 2016 , 2015 or 2014 . The fair value of restricted stock units is estimated as the closing price of the Company's common stock on the date of grant. The estimated fair value of stock-based compensation awards is amortized to expense on a straight-line basis over the requisite service periods. As stock-based compensation expense recognized is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company’s forfeiture rate was calculated based on its historical experience of awards which ultimately vested.
Income per Common Share	Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution that would occur if outstanding stock options were exercised utilizing the treasury stock method.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 requires entities to recognize revenue through the application of a five-step model, which includes identification of the contract, identification of the performance obligations, determination of the transaction price, allocation of the transaction price to the performance obligations and recognition of revenue as the entity satisfies the performance obligations. Subsequently, the FASB issued the following accounting standard updates related to Topic 606, Revenue Contracts with Customers: • ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) in March 2016. ASU 2016-08 does not change the core principle of revenue recognition in Topic 606 but clarifies the implementation guidance on principal versus agent considerations. • ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing in April 2016. ASU 2016-10 does not change the core principle of revenue recognition in Topic 606 but clarifies the implementation guidance on identifying performance obligations and the licensing • ASUs No. 2016-12 and 2016-20, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. These ASUs do not change the core principle of revenue recognition in Topic 606 but clarifies the implementation guidance on a few narrow areas and adds some practical expedients to the guidance. The amendments are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. During Fiscal 2016, the Company established an internal implementation team and engaged a third-party advisory firm to assist in the implementation of the new standard. The Company is currently finalizing its assessment relative to the adoption of this guidance, and currently does not expect it will have significant impact on its consolidated financial statements. The Company is also evaluating whether to adopt the guidance using the full or modified retrospective basis, and will likely make that determination during the first half of Fiscal 2017. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). The amendments require that an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company adopted this guidance effective January 1, 2017 and does not expect this ASU to have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. ASU 2016-02 requires that a lessee should recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for the fiscal year beginning after December 15, 2018 (including interim periods within that year) using a modified retrospective approach and early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of ASU 2016-02 on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends Accounting Standards Codification (Topic 718), Compensation – Stock Compensation. ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted this guidance effective January 1, 2017. Under this standard, all excess tax benefits and tax deficiencies related to stock compensation will be recognized as income tax expense or benefit in the consolidated statement of operations. The Company will recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period, subject to normal valuation allowance considerations. The standard will be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of Fiscal 2017. The Company does not expect the provisions of this ASU to have a material impact on its consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which amends ASC 326. The new guidance differs from existing GAAP wherein previous objectives generally delayed recognition of credit losses until the loss was probable. ASU 2016-13 eliminates the probable initial recognition threshold and, instead, reflect an entity’s current estimate of all expected credit losses. The use of forecasted information is intended to incorporate more timely information in the estimate of expected credit loss. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2019, and interim periods within that fiscal year, and early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of ASU 2016-13 on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. ASU 2016-15 is effective for the fiscal year beginning after December 15, 2017, and interim periods within that fiscal year, and early adoption is permitted. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively as of the earliest date practicable. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740) - Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires an entity to recognize income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This removes the exception to postpone recognition until the asset has been sold to an outside party. ASU 2016-16 is effective for fiscal year beginning after December 15, 2017 using a modified retrospective approach, and early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of ASU 2016-16 on its consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows - Restricted Cash (Topic 230), which amends the existing guidance relating to the disclosure of restricted cash and restricted cash equivalents on the statement of cash flows. ASU 2016-18 is effective for the fiscal year beginning after December 15, 2017, and interim periods within that fiscal year, and early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of ASU 2016-18 on its Consolidated Statements of Cash Flows. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805) to provide a more robust framework to use in determining when a set of assets and activities is a business. ASU 2017-01 is effective for the fiscal year beginning after December 15, 2017, and interim periods within that year and early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.
Foreign Currency Translation	Foreign Currency Translation The Company’s foreign subsidiaries use their local currency as their functional currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date. Income and expense accounts are translated at the average monthly exchange rates during the year. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the consolidated balance sheets.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation.

Organization and Summary of S28

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Changes in Estimated Product Warranty Liabilities	Changes in the Company’s estimated product warranty liabilities were as follows (in thousands): 2016 2015 2014 Balance, January 1 $ 314 $ 675 $ 955 Utilization of accrual (155 ) (299 ) (676 ) Warranty expense (recoveries) 621 (62 ) 396 Balance, December 31 $ 780 $ 314 $ 675
Net Sales by Geographic Area	For the three years ended December 31, 2016 , 2015 and 2014 , net sales by geographic area were as follows (in thousands): Year Ended December 31, 2016 2015 2014 United States $ 218,757 81.6 % $ 161,803 81.8 % $ 132,205 80.4 % Other Countries 49,488 18.4 36,089 18.2 32,320 19.6 Total $ 268,245 100.0 % $ 197,892 100.0 % $ 164,525 100.0 %
Weighted Average Number of Shares Outstanding and Income Per Share	The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): For the Year Ended December 31, 2016 2015 2014 Numerator for basic and diluted earnings per share: Net income $ 17,297 $ 19,933 $ 19,918 Denominator: Weighted average shares outstanding—basic 52,667 53,548 52,948 Dilutive effect of stock-based awards 869 1,090 1,552 Diluted weighted average shares outstanding 53,536 54,638 54,500 Anti-dilutive stock-based awards excluded 443 198 177 Net income per common share: Basic $ 0.33 $ 0.37 $ 0.38 Diluted $ 0.32 $ 0.36 $ 0.37

Cash, Cash Equivalents and In29

Cash, Cash Equivalents and Investments (Tables)	12 Months Ended
	Dec. 31, 2016
Cash and Cash Equivalents [Abstract]
Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type	The following tables summarize the Company's cash, cash equivalents, and held-to-maturity investments at December 31 (in thousands): As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 32,802 $ — $ — $ 32,802 $ 32,802 $ — $ — Level 1: Money market funds 7,849 — — 7,849 7,849 — — Corporate bonds 33,379 — (57 ) 33,322 — 33,379 — Subtotal 41,228 — (57 ) 41,171 7,849 33,379 — Level 2: State and municipal obligations 14,477 — (10 ) 14,467 — 14,243 234 Certificates of deposit 793 — — 793 — 793 — Subtotal 15,270 — (10 ) 15,260 — 15,036 234 Total $ 89,300 $ — $ (67 ) $ 89,233 $ 40,651 $ 48,415 $ 234 As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 57,137 $ — $ — $ 57,137 $ 57,137 $ — $ — Level 1: Money market funds 2,389 — — 2,389 2,389 — — Corporate bonds 36,406 — (70 ) 36,336 — 35,677 729 Subtotal 38,795 — (70 ) 38,725 2,389 35,677 729 Level 2: State and municipal obligations 19,002 11 (9 ) 19,004 — 12,000 7,002 Certificates of deposit 3,371 — — 3,371 — 2,577 794 Subtotal 22,373 11 (9 ) 22,375 — 14,577 7,796 Total $ 118,305 $ 11 $ (79 ) $ 118,237 $ 59,526 $ 50,254 $ 8,525
Summary of Amortized Cost and Fair Value of Short-term and Long-term Investments	The following table summarizes the amortized cost and fair value of the short-term and long-term investments held by the Company at December 31, 2016 by contractual maturity (in thousands): Amortized Cost Fair Value Due in less than one year $ 48,415 $ 48,349 Due after one year, through two years 234 233 Due after two years — — Total short-term and long-term investments $ 48,649 $ 48,582

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory	Inventories consisted of the following at December 31 (in thousands): 2016 2015 Raw materials $ 18,002 $ 8,853 Finished goods 16,839 6,910 Total inventory $ 34,841 $ 15,763

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following at December 31 (in thousands): Estimated Useful Life 2016 2015 Land N/A $ 2,900 $ 2,900 Building and leasehold improvements 3-39 years 15,295 15,246 Production equipment 3-7 years 19,849 18,689 Computer equipment 3-5 years 7,985 8,048 Furniture and office equipment 5-7 years 4,990 4,116 Vehicles 5 years 675 713 Website development costs 3 years 601 601 Capitalized software development costs 3 years 3,695 3,670 Construction-in-process N/A 5,813 3,885 Total cost 61,803 57,868 Less: Accumulated depreciation (37,799 ) (36,020 ) Property and equipment, net $ 24,004 $ 21,848

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill for the year ended December 31, 2016 were as follows (in thousands): Balance, January 1, 2015 $ 9,596 Goodwill acquired 1,615 Purchase accounting adjustments (520 ) Foreign currency translation adjustments (249 ) Balance, December 31, 2016 $ 10,442
Intangible Assets Other than goodwill	Intangible assets (other than goodwill) consisted of the following (in thousands): December 31, 2016 December 31, 2015 Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Amortized: Domain names 5-10 years $ 3,161 $ (125 ) $ 3,036 $ 125 $ (120 ) $ 5 Issued patents 4-15 years 1,942 (780 ) 1,162 1,866 (659 ) 1,207 Issued trademarks 3-11 years 655 (320 ) 335 603 (255 ) 348 Customer relationships 4-8 years 914 (240 ) 674 1,035 (93 ) 942 Non-compete agreements 3-4 years 465 (236 ) 229 464 (164 ) 300 Developed technology 5-7 years 8,661 (824 ) 7,837 3,470 (326 ) 3,144 Total amortized 15,798 (2,525 ) 13,273 7,563 (1,617 ) 5,946 Not amortized: TASER trademark 900 900 900 900 Patents and trademarks pending 1,045 1,045 742 742 Total not amortized 1,945 1,945 1,642 1,642 Total intangible assets $ 17,743 $ (2,525 ) $ 15,218 $ 9,205 $ (1,617 ) $ 7,588
Estimated Amortization Expense of Intangible Assets	Estimated amortization for intangible assets with definitive lives for the next five years, and thereafter, is as follows for the years ended December 31 (in thousands): 2017 $ 2,281 2018 2,268 2019 2,145 2020 2,084 2021 2,076 Thereafter 2,419 Total $ 13,273

Other Long-Term Assets (Tables)

Other Long-Term Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Long-Term Assets	Other long-term assets consisted of the following at December 31 (in thousands): 2016 2015 Cash surrender value of corporate-owned life insurance policies (Note 1) $ 3,240 $ 2,180 Prepaid commissions (i) 5,302 3,543 Restricted cash (ii) 3,317 — Prepaid expenses, deposits and other (iii) 2,058 246 $ 13,917 $ 5,969 (i) Prepaid commissions represent customer acquisition costs to secure long-term contracts. The Company capitalizes incremental and direct costs related to a specific contract and recognizes expense over the term of the contract. (ii) As of December 31, 2016, restricted cash primarily consisted of $2.7 million of sales proceeds related to a long-term contract with a specific customer. These proceeds are held in escrow until certain billing milestones are achieved, and then specified amounts are transferred to the Company's operating accounts. Restricted also contained $0.6 million related to a performance guarantee related to an international customer sales contract. (iii) Included in long-term assets as of December 31, 2016 was $1.8 million of funds deposited in escrow related to contingent consideration in connection with a business combination (see Note 15). The funds will be held in escrow and released to selling shareholders if certain conditions are subsequently met. If the conditions are not met, the funds will be released back to the Company.

Deferred Revenue (Tables)

Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2016
Deferred Revenue Disclosure [Abstract]
Summary of Deferred Revenue	Deferred revenue consisted of the following at December 31 (in thousands): December 31, 2016 December 31, 2015 Current Long-Term Total Current Long-Term Total Warranty: TASER Weapons $ 9,783 $ 17,319 $ 27,102 $ 7,278 $ 13,982 $ 21,260 Axon 3,979 2,926 6,905 2,332 2,344 4,676 13,762 20,245 34,007 9,610 16,326 25,936 Hardware: TASER Weapons 1,702 4,390 6,092 952 2,459 3,411 Axon 9,850 11,205 21,055 786 7,382 8,168 11,552 15,595 27,147 1,738 9,841 11,579 Axon Services 19,626 4,214 23,840 9,303 4,023 13,326 Other 197 — 197 200 — 200 Total $ 45,137 $ 40,054 $ 85,191 $ 20,851 $ 30,190 $ 51,041 December 31, 2016 December 31, 2015 Current Long-Term Total Current Long-Term Total TASER Weapons and other $ 11,682 $ 21,709 $ 33,391 $ 8,430 $ 16,441 $ 24,871 Axon 33,455 18,345 51,800 12,421 13,749 26,170 Total $ 45,137 $ 40,054 $ 85,191 $ 20,851 $ 30,190 $ 51,041

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consisted of the following at December 31 (in thousands): 2016 2015 Accrued salaries, benefits and bonus $ 6,474 $ 3,637 Accrued professional, consulting and lobbying 3,673 1,098 Accrued warranty expense 780 314 Accrued income and other taxes 4,581 1,215 Other accrued expenses 2,740 2,379 Accrued liabilities $ 18,248 $ 8,643

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments Under Non-Cancelable Leases	Future minimum lease payments under non-cancelable leases at December 31, 2016 , are as follows (in thousands): Operating Capital 2017 $ 1,440 $ 36 2018 1,278 36 2019 646 36 2020 653 33 2021 596 — Thereafter 504 — Total minimum lease payments $ 5,117 141 Less: Amount representing interest (11 ) Capital lease obligation $ 130
Loss Contingencies	With respect to each of the pending lawsuits, the following table lists the name of plaintiff, the date the Company was served with process, the jurisdiction in which the case is pending, the type of claim and the status of the matter. Plaintiff Month Served Jurisdiction Claim Type Status Derbyshire Nov-09 Ontario, Canada Superior Court of Justice Officer Injury Discovery Phase Shymko Dec-10 The Queen's Bench, Winnipeg Centre, Manitoba Wrongful Death Pleading Phase Ramsey Jan-12 12th Judicial Circuit Court, Broward County, FL Wrongful Death Discovery Phase Firman Apr-12 Ontario, Canada Superior Court of Justice Wrongful Death Dismissal Pending Schrock Sep-14 San Bernardino County Superior Court, CA Wrongful Death Motion of Summary Judgment Granted on all claims except negligent design and manufacture, subject to repleading by Plaintiff. Plaintiff filed an amended complaint for negligent design claims as well as a Petition for Writ of Mandate or Prohibition Petition from the Court; which writ was summarily denied. Trial scheduled for August 14, 2017 Bennett Sep-15 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Discovery Phase Suarez Sep-16 US District Court, Southern District of Florida Wrongful Death Pleading Phase Masters Nov-16 US District Court, Western District of Missouri Suspect Injury Pleading Phase
Summary of Cases Dismissed or Judgment Entered	Plaintiff Month Served Jurisdiction Claim Type Status Doan Apr-10 The Queen's Bench Alberta, Red Deer Judicial Dist. Wrongful Death Dismissed Hernandez/Llach Sep-15 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Dismissed Williams Aug-16 US District Court for the Northern District of Georgia Wrongful Death Dismissed Ramos Dec-16 US District Court for the Northern District of Illinois Conspiracy and negligent spoliation Dismissed
Information Regarding the Company's Insurance Coverage	Remaining insurance coverage is based on information received from the Company’s insurance provider (in millions). Policy Year Policy Start Date Policy End Date Insurance Coverage Deductible Amount Defense Costs Covered Remaining Insurance Coverage Active Cases and Cases on Appeal 2009 12/15/2008 12/15/2009 $ 10.0 $ 1.0 N $ 10.0 Derbyshire 2010 12/15/2009 12/15/2010 10.0 1.0 N 10.0 Shymko 2011 12/15/2010 12/15/2011 10.0 1.0 N 10.0 n/a Jan-Jun 2012 12/15/2011 6/25/2012 7.0 1.0 N 7.0 Ramsey, Firman Jul-Dec 2012 6/25/2012 12/15/2012 12.0 1.0 N 12.0 n/a 2013 12/15/2012 12/15/2013 12.0 1.0 N 12.0 n/a 2014 12/15/2013 12/15/2014 11.0 4.0 N 11.0 Schrock 2015 12/15/2014 12/15/2015 10.0 5.0 N 10.0 Bennett 2016 12/15/2015 12/15/2016 10.0 5.0 N 10.0 Suarez, Masters

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Income before income taxes included the following components for the years ended December 31 (in thousands): 2016 2015 2014 United States $ 38,414 $ 42,761 $ 32,751 Foreign (6,917 ) (7,400 ) (440 ) Total $ 31,497 $ 35,361 $ 32,311
Components of Deferred Income Tax Assets and Liabilities	Significant components of the Company’s deferred income tax assets and liabilities are as follows at December 31 (in thousands): 2016 2015 Deferred income tax assets: Net operating loss carryforward $ 2,405 $ 649 Deferred revenue 11,537 6,762 Deferred compensation 1,695 1,252 Inventory reserve 1,126 956 Non-qualified and non-employee stock option expense 4,410 3,393 Capitalized research and development 1,991 3,348 Research and development tax credit carryforward 2,722 2,386 Reserves, accruals, and other 1,239 1,067 Total deferred income tax assets 27,125 19,813 Deferred income tax liabilities: Depreciation (2,364 ) (2,228 ) Amortization (1,473 ) (1,979 ) Other (294 ) (187 ) Total deferred income tax liabilities (4,131 ) (4,394 ) Net deferred income tax assets before valuation allowance 22,994 15,419 Valuation allowance (3,479 ) (1,700 ) Net deferred income tax assets $ 19,515 $ 13,719
Significant Components of the Provision for Income Taxes	Significant components of the provision for income taxes are as follows for the years ended December 31 (in thousands) 2016 2015 2014 Current: Federal $ 16,346 $ 13,594 $ 7,793 State 1,534 996 800 Foreign 1,050 — — Total current 18,930 14,590 8,593 Deferred: Federal (4,145 ) 288 2,656 State (977 ) 984 942 Foreign (45 ) (278 ) — Total deferred (5,167 ) 994 3,598 Tax provision recorded as an increase (decrease) in liability for unrecorded tax benefits 437 (156 ) 202 Provision for income taxes $ 14,200 $ 15,428 $ 12,393
Reconciliation of the Company's Effective Income Tax Rate to the Federal Statutory Rate	A reconciliation of the Company’s effective income tax rate to the federal statutory rate follows for the years ended December 31 (in thousands): 2016 2015 2014 Federal income tax at the statutory rate $ 11,024 $ 12,347 $ 11,236 State income taxes, net of federal benefit 889 1,061 1,433 Difference between statutory and foreign tax rates (i) 1,521 2,442 — Permanent differences (ii) (457 ) (205 ) 98 Research and development (1,928 ) (1,050 ) (452 ) Return to provision adjustment 327 (67 ) 28 Change in liability for unrecognized tax benefits 700 (156 ) 202 Incentive stock option benefit (77 ) (144 ) (616 ) Change in valuation allowance 1,779 1,200 500 Tax effects of intercompany transactions 630 — — Other (208 ) — (36 ) Provision for income taxes $ 14,200 $ 15,428 $ 12,393 Effective tax rate 45.1 % 43.6 % 38.4 % (i) The difference between statutory and foreign tax rates of $1.5 million was largely driven by losses incurred in a foreign entity for which no tax benefit will be realized, partially reduced by a tax benefit for foreign entities for which the statutory tax rate is lower than the U.S. statutory tax rate. (ii) Permanent differences include certain expenses that are not deductible for tax purposes including lobbying fees as well as favorable items including the domestic production activities deduction.
Roll Forward of Liability for Unrecognized Tax Benefits Exclusive of Accrued Interest	The following table presents a roll forward of the Company's liability for unrecognized tax benefits, exclusive of accrued interest, as of December 31 (in thousands): 2016 2015 2014 Balance, beginning of period $ 3,396 $ 3,325 $ 3,110 Decrease in previous year tax positions — (389 ) — Increase in current year tax positions 448 270 121 Decrease due to lapse of statute of limitations — (14 ) — Increase related to adjustment of previous estimates of activity 206 204 94 Balance, end of period $ 4,050 $ 3,396 $ 3,325

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Summary of Restricted Stock Unit Activity	The following table summarizes RSU activity for the years ended December 31 (number of units and aggregate intrinsic value in thousands): 2016 2015 2014 Number of Units Weighted Average Grant-Date Fair Value Number of Units Weighted Average Grant-Date Fair Value Number of Units Weighted Average Grant-Date Fair Value Units outstanding, beginning of year 1,139 $ 19.30 1,226 $ 13.23 1,279 $ 9.67 Granted 718 19.75 516 26.18 554 16.98 Released (414 ) 15.91 (488 ) 11.82 (433 ) 7.61 Forfeited (113 ) 21.65 (115 ) 16.72 (174 ) 13.08 Units outstanding, end of year 1,330 20.40 1,139 19.30 1,226 13.23 Aggregate intrinsic value at year end (in thousands) $ 32,239
Summary of the Company's Stock Options Activity	The following table summarizes stock option activity for the years ended December 31 (number of options in thousands): 2016 2015 2014 Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price Options outstanding, beginning of year 1,103 $ 5.37 1,641 $ 5.26 3,366 $ 6.15 Granted — — — — — — Exercised (95 ) 5.02 (525 ) 4.95 (1,644 ) 6.69 Expired / terminated — — (13 ) 7.27 (81 ) 16.59 Options outstanding, end of year 1,008 5.40 1,103 5.37 1,641 5.26 Options exercisable, end of year 977 5.42 1,072 5.39 1,606 5.27 Options expected to vest, end of year 25 4.75
Summary of Stock Options Outstanding and Exercisable	The following table summarizes information about stock options outstanding and exercisable as of December 31, 2016 (number of options in thousands): Options Outstanding Options Exercisable Range of Exercise Price Number of Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Number of Options Exercisable Weighted Average Price Weighted Average Remaining Contractual Life (Years) $4.00 - $5.00 722 $ 4.65 2.66 691 $ 4.64 2.69 $5.01 - $7.00 112 5.57 1.70 112 5.57 1.70 $7.01 - $10.00 106 7.25 1.19 106 7.25 1.19 $10.01 - $16.23 68 10.30 0.40 68 10.30 0.40 $4.00 - $16.23 1,008 5.40 2.25 977 5.42 2.25
Reported Share-Based Compensation	The Company accounts for stock-based compensation using the fair-value method. Reported stock-based compensation was classified as follows for the years ended December 31 (in thousands): 2016 2015 2014 Cost of products sold and services delivered $ 342 $ 402 $ 204 Sales, general and administrative expenses 5,707 4,285 3,555 Research and development expenses 3,320 2,576 1,820 Total stock-based compensation $ 9,369 $ 7,263 $ 5,579

Business Acquisitions (Tables)

Business Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Schedule of Allocation of Purchase Price	The major classes of assets and liabilities to which the Company has allocated the purchase price, on a preliminary basis, were as follows (in thousands): Developed technology $ 5,210 Goodwill 1,615 Total purchase price $ 6,825 The major classes of assets and liabilities to which the Company allocated the purchase price was as follows (in thousands): Accounts receivable and other current assets $ 590 Inventory 35 Property and equipment 53 Intangible assets 4,145 Goodwill 5,496 Accounts payable and accrued liabilities (697 ) Deferred revenue (111 ) Deferred income tax liabilities, net (688 ) Total purchase price $ 8,823 The major classes of assets and liabilities to which the Company allocated the purchase price was as follows (in thousands): Accounts receivable $ 726 Inventory 497 Property and equipment 583 Other Assets 20 Intangible assets 881 Goodwill 1,441 Accounts payable and accrued liabilities (207 ) Notes payable (169 ) Income tax liabilities (438 ) Total purchase price $ 3,334

Segment Data (Tables)

Segment Data (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Summary of Operational Information Relative to the Company's Reportable Segments	Information relative to the Company’s reportable segments was as follows (in thousands): For the year ended December 31, 2016 TASER Weapons Axon Total Product sales $ 202,644 $ 35,929 $ 238,573 Service revenue — 29,672 29,672 Net sales 202,644 65,601 268,245 Cost of products sold 61,930 29,606 91,536 Cost of services delivered — 6,173 6,173 Gross margin 140,714 29,822 170,536 Sales, general and administrative 63,617 44,459 108,076 Research and development 5,887 24,722 30,609 Income (loss) from operations $ 71,210 $ (39,359 ) $ 31,851 Purchase of property and equipment $ 4,129 $ 828 $ 4,957 Purchase of intangible assets 262 3,233 3,495 Purchase of intangible assets in connection with business acquisitions — 6,825 6,825 Depreciation and amortization 2,207 1,451 3,658 For the year ended December 31, 2015 TASER Axon Total Product sales $ 162,375 $ 22,855 $ 185,230 Service revenue — 12,662 12,662 Net sales 162,375 35,517 197,892 Cost of products sold 48,821 16,201 65,022 Cost of services delivered — 4,223 4,223 Gross margin 113,554 15,093 128,647 Sales, general and administrative 47,640 22,058 69,698 Research and development 4,470 19,144 23,614 Income (loss) from operations $ 61,444 $ (26,109 ) $ 35,335 Purchase of property and equipment $ 4,159 $ 1,844 $ 6,003 Purchase of intangible assets 277 224 501 Purchase of property and equipment and intangible assets in connection with business acquisitions 1,453 11,146 12,599 Depreciation and amortization 2,311 980 3,291 For the year ended December 31, 2014 TASER Axon Total Product sales $ 145,613 $ 14,700 $ 160,313 Service revenue — 4,212 4,212 Net sales 145,613 18,912 164,525 Cost of products sold 47,680 13,233 60,913 Cost of services delivered — 2,064 2,064 Gross margin 97,933 3,615 101,548 Sales, general and administrative 42,989 11,169 54,158 Research and development 3,872 11,013 14,885 Income (loss) from operations $ 51,072 $ (18,567 ) $ 32,505 Purchase of property and equipment $ 2,233 $ 272 $ 2,505 Purchase of intangible assets 180 3 183 Depreciation and amortization 3,936 381 4,317

Selected Quarterly Financial 41

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data	Selected quarterly financial data for years ended December 31, 2016 and 2015 follows (in thousands, except per share data): Quarter Ended March 31, June 30, September 30, December 31, 2016 2016 2016 2016 Net sales $ 55,530 $ 58,756 $ 71,882 $ 82,077 Gross margin 36,902 37,299 46,565 49,770 Net income 3,463 3,650 3,843 6,341 Earnings per share (1) : Basic $ 0.06 $ 0.07 $ 0.07 $ 0.12 Diluted $ 0.06 $ 0.07 $ 0.07 $ 0.12 Quarter Ended March 31, June 30, September 30, December 31, 2015 2015 2015 2015 Net sales $ 44,762 $ 46,713 $ 50,376 $ 56,041 Gross margin 29,868 30,723 31,068 36,988 Net income 7,205 6,103 1,521 5,104 Earnings per share (1) : Basic $ 0.14 $ 0.11 $ 0.03 $ 0.10 Diluted $ 0.13 $ 0.11 $ 0.03 $ 0.09 (1) Basic and diluted earnings per share are computed independently for each of the quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted earnings per share.

Supplemental Disclosure to Ca42

Supplemental Disclosure to Cash Flows (Tables)	12 Months Ended
	Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Summary of Supplemental Non-Cash and Other Cash Flow Information	Supplemental non-cash and other cash flow information were as follows for the years ended December 31 (in thousands): 2016 2015 2014 Cash paid for income taxes, net of refunds $ 14,048 $ 6,759 $ 386 Non-cash transactions: Contingent consideration related to business combinations $ 3,325 $ 952 $ — Property and equipment purchases in accounts payable 82 315 270 Purchase of assets under capital lease obligations 134 — —

Organization and Summary of S43

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)SegmentDepositorySource	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2012
Summary Of Significant Accounting Policy [Line Items]
Impairment losses	$ 0	$ 0	$ 0
Number of revenue sources | Source	2
Service term for services purchased	1 year
Accounts and notes receivable related to purchases		0
Advertising cost	$ 400,000	600,000	300,000
Warranty period	1 year
Research and development costs	$ 30,609,000	23,614,000	$ 14,885,000
Allowance for doubtful accounts	$ 443,000	$ 322,000
Number of depository institutions | Depository	5
Aggregate balances in depository institution accounts	$ 33,200,000
Percentage of total net sales represented	10.00%	10.00%	10.00%
Accounts and notes receivable by customers one	14.50%	12.50%
Cash surrender value of corporate-owned life insurance policies (Note 1)	$ 3,240,000	$ 2,180,000
Number of reportable segments of company | Segment	2
Minimum
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased	1 year			3 years
Maximum
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased	5 years			5 years
Extended Product Warranty
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased	5 years	5 years
Extended Product Warranty | Minimum
Summary Of Significant Accounting Policy [Line Items]
Period of extended warranty after expiration of standard warranty	1 year
Extended Product Warranty | Maximum
Summary Of Significant Accounting Policy [Line Items]
Period of extended warranty after expiration of standard warranty	5 years
Evidence. Com
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased		2 years 6 months

Organization and Summary of S44

Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Product Warranty Liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Movement in Standard and Extended Product Warranty
Balance, January 1	$ 314	$ 675	$ 955
Utilization of accrual	(155)	(299)	(676)
Warranty expense (recoveries)	621	(62)	396
Balance, December 31	$ 780	$ 314	$ 675

Organization and Summary of S45

Organization and Summary of Significant Accounting Policies - Net Sales by Geographic Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Net sales by geographic area	$ 268,245	$ 197,892	$ 164,525
Percentage of net sales by geographic area	100.00%	100.00%	100.00%
United States
Segment Reporting Information [Line Items]
Net sales by geographic area	$ 218,757	$ 161,803	$ 132,205
Percentage of net sales by geographic area	81.60%	81.80%	80.40%
Other Countries
Segment Reporting Information [Line Items]
Net sales by geographic area	$ 49,488	$ 36,089	$ 32,320
Percentage of net sales by geographic area	18.40%	18.20%	19.60%

Organization and Summary of S46

Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Numerator for basic and diluted earnings per share:
Net income	$ 6,341	$ 3,843	$ 3,650	$ 3,463	$ 5,104	$ 1,521	$ 6,103	$ 7,205	$ 17,297	$ 19,933	$ 19,918
Denominator:
Weighted average shares outstanding—basic									52,667	53,548	52,948
Dilutive effect of stock-based awards (in shares)									869	1,090	1,552
Diluted weighted average shares outstanding									53,536	54,638	54,500
Anti-dilutive stock-based awards excluded (in shares)									443	198	177
Net income per common share:
Basic (in dollars per share)	$ 0.12	$ 0.07	$ 0.07	$ 0.06	$ 0.10	$ 0.03	$ 0.11	$ 0.14	$ 0.33	$ 0.37	$ 0.38
Diluted (in dollars per share)	$ 0.12	$ 0.07	$ 0.07	$ 0.06	$ 0.09	$ 0.03	$ 0.11	$ 0.13	$ 0.32	$ 0.36	$ 0.37

Cash, Cash Equivalents, and Inv

Cash, Cash Equivalents, and Investments - Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	$ 89,300	$ 118,305
Gross Unrealized Gains	0	11
Gross Unrealized Losses	(67)	(79)
Fair Value	89,233	118,237
Cash and Cash Equivalents	40,651	59,526
Short-term investments	48,415	50,254
Long-term investments	234	8,525
Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	41,228	38,795
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(57)	(70)
Fair Value	41,171	38,725
Cash and Cash Equivalents	7,849	2,389
Short-term investments	33,379	35,677
Long-term investments	0	729
Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	15,270	22,373
Gross Unrealized Gains	0	11
Gross Unrealized Losses	(10)	(9)
Fair Value	15,260	22,375
Cash and Cash Equivalents	0	0
Short-term investments	15,036	14,577
Long-term investments	234	7,796
Level 2 | State and municipal obligations
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	14,477	19,002
Gross Unrealized Gains	0	11
Gross Unrealized Losses	(10)	(9)
Fair Value	14,467	19,004
Cash and Cash Equivalents	0	0
Short-term investments	14,243	12,000
Long-term investments	234	7,002
Level 2 | Certificates of deposit
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	793	3,371
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	793	3,371
Cash and Cash Equivalents	0	0
Short-term investments	793	2,577
Long-term investments	0	794
Cash
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	32,802	57,137
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	32,802	57,137
Cash and Cash Equivalents	32,802	57,137
Short-term investments	0	0
Long-term investments	0	0
Money market funds | Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	7,849	2,389
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	7,849	2,389
Cash and Cash Equivalents	7,849	2,389
Short-term investments	0	0
Long-term investments	0	0
Corporate bonds | Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	33,379	36,406
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(57)	(70)
Fair Value	33,322	36,336
Cash and Cash Equivalents	0	0
Short-term investments	33,379	35,677
Long-term investments	$ 0	$ 729

Cash, Cash Equivalents, and I48

Cash, Cash Equivalents, and Investments - Summary of Amortized Cost and Fair Value of Short-term and Long-term Investments (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	$ 48,415	$ 50,254
Due after one year, through two years	234	$ 8,525
Amortized Cost
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	48,415
Due after one year, through two years	234
Due after two years	0
Total short-term and long-term investments	48,649
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	48,349
Due after one year, through two years	233
Due after two years	0
Total short-term and long-term investments	$ 48,582

Inventory (Detail)

Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 18,002	$ 8,853
Finished goods	16,839	6,910
Total inventory	$ 34,841	$ 15,763

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total cost	$ 61,803	$ 57,868
Less: Accumulated depreciation	(37,799)	(36,020)
Property and equipment, net	24,004	21,848
Land
Property, Plant and Equipment [Line Items]
Total cost	2,900	2,900
Building and Leasehold Improvements
Property, Plant and Equipment [Line Items]
Total cost	$ 15,295	15,246
Building and Leasehold Improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Building and Leasehold Improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	39 years
Production Equipment
Property, Plant and Equipment [Line Items]
Total cost	$ 19,849	18,689
Production Equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Production Equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Computer Equipment
Property, Plant and Equipment [Line Items]
Total cost	$ 7,985	8,048
Computer Equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Computer Equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Furniture and Office Equipment
Property, Plant and Equipment [Line Items]
Total cost	$ 4,990	4,116
Furniture and Office Equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Furniture and Office Equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Total cost	$ 675	713
Website Development Costs
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Total cost	$ 601	601
Capitalized Software Development Costs
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Total cost	$ 3,695	3,670
Construction-in-Process
Property, Plant and Equipment [Line Items]
Total cost	$ 5,813	$ 3,885

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense relative to property and equipment	$ 2.5	$ 2.3	$ 4
Cost of products sold and services provided	$ 0.7	$ 0.7	$ 2.8

Goodwill and Intangible Asset52

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Changes in carrying amount of goodwill
Balance, January 1, 2015	$ 9,596
Goodwill acquired	1,615
Purchase accounting adjustments	(520)
Foreign currency translation adjustments	(249)
Balance, December 31, 2016	$ 10,442

Goodwill and Intangible Asset53

Goodwill and Intangible Assets - Intangible Assets Other than Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Gross Carrying Amount	$ 15,798	$ 7,563
Accumulated Amortization	(2,525)	(1,617)
Total	13,273	5,946
Not amortized, Gross Carrying Amount	1,945	1,642
Intangible assets, Gross Carrying Amount	17,743	9,205
Intangible Assets, Net Carrying Amount	15,218	7,588
Amortization of Intangible Assets	900	800	$ 200
TASER trademark
Acquired Indefinite-lived Intangible Assets [Line Items]
Not amortized, Gross Carrying Amount	900	900
Patents and trademarks pending
Acquired Indefinite-lived Intangible Assets [Line Items]
Not amortized, Gross Carrying Amount	1,045	742
Domain names
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Gross Carrying Amount	3,161	125
Accumulated Amortization	(125)	(120)
Total	$ 3,036	5
Domain names | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	5 years
Domain names | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	10 years
Issued patents
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Gross Carrying Amount	$ 1,942	1,866
Accumulated Amortization	(780)	(659)
Total	$ 1,162	1,207
Issued patents | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	4 years
Issued patents | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	15 years
Issued trademarks
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Gross Carrying Amount	$ 655	603
Accumulated Amortization	(320)	(255)
Total	$ 335	348
Issued trademarks | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	3 years
Issued trademarks | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	11 years
Customer relationships
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Gross Carrying Amount	$ 914	1,035
Accumulated Amortization	(240)	(93)
Total	$ 674	942
Customer relationships | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	4 years
Customer relationships | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	8 years
Non-compete agreements
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Gross Carrying Amount	$ 465	464
Accumulated Amortization	(236)	(164)
Total	$ 229	300
Non-compete agreements | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	3 years
Non-compete agreements | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	4 years
Developed technology
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Gross Carrying Amount	$ 8,661	3,470
Accumulated Amortization	(824)	(326)
Total	$ 7,837	$ 3,144
Developed technology | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	5 years
Developed technology | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized, Useful Life	7 years

Goodwill and Intangible asset54

Goodwill and Intangible assets - Estimated Amortization Expense of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2,017	$ 2,281
2,018	2,268
2,019	2,145
2,020	2,084
2,021	2,076
Thereafter	2,419
Total	$ 13,273	$ 5,946

Other Long-Term Assets (Details

Other Long-Term Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Restricted Cash and Cash Equivalents Items [Line Items]
Cash surrender value of corporate-owned life insurance policies (Note 1)	$ 3,240	$ 2,180
Prepaid commissions	5,302	3,543
Restricted cash	3,317	0
Prepaid expenses, deposits and other	2,058	246
Other long-term assets	13,917	$ 5,969
Axon Artificial Intelligence
Restricted Cash and Cash Equivalents Items [Line Items]
Prepaid expenses, deposits and other	1,800
Customer A
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	2,700
Customer B
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 600

Deferred Revenue - Summary of D

Deferred Revenue - Summary of Deferred Revenue (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	$ 45,137	$ 20,851
Long-term portion of deferred revenue	40,054	30,190
Total deferred revenue	85,191	51,041
Warranty
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	13,762	9,610
Long-term portion of deferred revenue	20,245	16,326
Total deferred revenue	34,007	25,936
Hardware Equipment
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	11,552	1,738
Long-term portion of deferred revenue	15,595	9,841
Total deferred revenue	27,147	11,579
AXON services
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	19,626	9,303
Long-term portion of deferred revenue	4,214	4,023
Total deferred revenue	23,840	13,326
Other
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	197	200
Long-term portion of deferred revenue	0	0
Total deferred revenue	197	200
TASER Weapons | Warranty
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	9,783	7,278
Long-term portion of deferred revenue	17,319	13,982
Total deferred revenue	27,102	21,260
TASER Weapons | Hardware Equipment
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	1,702	952
Long-term portion of deferred revenue	4,390	2,459
Total deferred revenue	6,092	3,411
Axon
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	33,455	12,421
Long-term portion of deferred revenue	18,345	13,749
Total deferred revenue	51,800	26,170
Axon | Warranty
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	3,979	2,332
Long-term portion of deferred revenue	2,926	2,344
Total deferred revenue	6,905	4,676
Axon | Hardware Equipment
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	9,850	786
Long-term portion of deferred revenue	11,205	7,382
Total deferred revenue	21,055	8,168
TASER Weapons and other
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	11,682	8,430
Long-term portion of deferred revenue	21,709	16,441
Total deferred revenue	$ 33,391	$ 24,871

Accrued Liabilities (Detail)

Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued salaries, benefits and bonus	$ 6,474	$ 3,637
Accrued professional, consulting and lobbying	3,673	1,098
Accrued warranty expense	780	314	$ 675	$ 955
Accrued income and other taxes	4,581	1,215
Other accrued expenses	2,740	2,379
Accrued liabilities	$ 18,248	$ 8,643

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2016USD ($)Case	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2016Lawsuit	Dec. 31, 2016Case	Sep. 30, 2011Case
Loss Contingencies [Line Items]
Rent expense under operating lease		$ 1.8	$ 1	$ 0.9
Open purchase order	$ 46	46
Number of active lawsuits against Company					8	8	55
Cases that were dismissed or judgment entered | Case	4
Severance costs		0.6
Letters of credit outstanding amount	$ 2.7	2.7
Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	5.7	5.7
Expiring May 2017 | Surety Bond
Loss Contingencies [Line Items]
Letters of credit outstanding amount	2.7	2.7
Expiring in 2018 | Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	0.4	0.4
Expiring in 2020 | Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	2.4	2.4
Expiring in 2021 and thereafter | Surety Bond
Loss Contingencies [Line Items]
Outstanding surety bonds expected to be released during period	2.9	2.9
Antoine di Zazzo vs. TASER International, Inc. | Pending Litigation
Loss Contingencies [Line Items]
Loss contingency, estimate of possible loss	0.6	$ 0.6
Minimum
Loss Contingencies [Line Items]
Operating leases, term (ranging from less than one year)		1 year
Amount payable on termination of contract	0.7	$ 0.7
Maximum
Loss Contingencies [Line Items]
Operating leases, term (ranging from less than one year)		6 years
Amount payable on termination of contract	$ 1.3	$ 1.3

Commitments and Contingencies59

Commitments and Contingencies - Lease Obligations (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 1,440
2,018	1,278
2,019	646
2,020	653
2,021	596
Thereafter	504
Total minimum lease payments	5,117
2,017	36
2,018	36
2,019	36
2,020	33
2,021	0
Thereafter	0
Total minimum lease payments	141
Less: Amount representing interest	(11)
Capital lease obligation	$ 130

Commitments and Contingencies60

Commitments and Contingencies - Information Regarding the Company's Insurance Coverage (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
2,009
Product Liability Contingency [Line Items]
Insurance Coverage	$ 10
Deductible Amount	1
Remaining Insurance Coverage	10
2,010
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
2,011
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
Jan - Jun 2012
Product Liability Contingency [Line Items]
Insurance Coverage	7
Deductible Amount	1
Remaining Insurance Coverage	7
Jul - Dec 2012
Product Liability Contingency [Line Items]
Insurance Coverage	12
Deductible Amount	1
Remaining Insurance Coverage	12
2,013
Product Liability Contingency [Line Items]
Insurance Coverage	12
Deductible Amount	1
Remaining Insurance Coverage	12
2,014
Product Liability Contingency [Line Items]
Insurance Coverage	11
Deductible Amount	4
Remaining Insurance Coverage	11
2,015
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	5
Remaining Insurance Coverage	10
2,016
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	5
Remaining Insurance Coverage	$ 10

Income Taxes - Income by Region

Income Taxes - Income by Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
United States	$ 38,414	$ 42,761	$ 32,751
Foreign	(6,917)	(7,400)	(440)
Income before provision for income taxes	$ 31,497	$ 35,361	$ 32,311

Income Taxes - Components of De

Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred income tax assets:
Net operating loss carryforward	$ 2,405	$ 649
Deferred revenue	11,537	6,762
Deferred compensation	1,695	1,252
Inventory reserve	1,126	956
Non-qualified and non-employee stock option expense	4,410	3,393
Capitalized research and development	1,991	3,348
Research and development tax credit carryforward	2,722	2,386
Reserves, accruals, and other	1,239	1,067
Total deferred income tax assets	27,125	19,813
Deferred income tax liabilities:
Depreciation	(2,364)	(2,228)
Amortization	(1,473)	(1,979)
Other	(294)	(187)
Total deferred income tax liabilities	(4,131)	(4,394)
Net deferred income tax assets before valuation allowance	22,994	15,419
Valuation allowance	(3,479)	(1,700)
Net deferred income tax assets	$ 19,515	$ 13,719

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Contingency [Line Items]
Tax expense resulting from share-based compensation tax benefits	$ 1,400	$ 6,900	$ 8,000
Deferred tax assets, state NOLs	1,800
Deferred tax assets, federal NOLs	900
Research and development tax credit studies	14,100
Liability for unrecognized tax benefits		3,900
Threshold to favorably impact effective tax rate	4,100
Unrecognized tax benefits, accrued interest	98	$ 55
ARIZONA | 2019
Income Tax Contingency [Line Items]
Minimum tax credit carryover	1,200
AUSTRALIA
Income Tax Contingency [Line Items]
Deferred tax assets, foreign NOLs	1,500
UNITED KINGDOM
Income Tax Contingency [Line Items]
Deferred tax assets, foreign NOLs	5,500
CANADA
Income Tax Contingency [Line Items]
Deferred tax assets, foreign NOLs	700
GERMANY
Income Tax Contingency [Line Items]
Deferred tax assets, foreign NOLs	1,100
Federal
Income Tax Contingency [Line Items]
Federal research and development credit carry forwards	43
State
Income Tax Contingency [Line Items]
Liability for unrecognized tax benefits	200
State | ARIZONA
Income Tax Contingency [Line Items]
State research and development credit carry forwards	$ 6,400

Income Taxes - Significant Comp

Income Taxes - Significant Components of the Provision (Benefit) for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current:
Federal	$ 16,346	$ 13,594	$ 7,793
State	1,534	996	800
Foreign	1,050	0	0
Total current	18,930	14,590	8,593
Deferred:
Federal	(4,145)	288	2,656
State	(977)	984	942
Foreign	(45)	(278)	0
Total deferred	(5,167)	994	3,598
Tax provision recorded as an increase (decrease) in liability for unrecorded tax benefits	437	(156)	202
Provision for income taxes	$ 14,200	$ 15,428	$ 12,393

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of the Company's Effective Income Tax Rate to the Federal Statutory Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Federal income tax at the statutory rate	$ 11,024	$ 12,347	$ 11,236
State income taxes, net of federal benefit	889	1,061	1,433
Difference between statutory and foreign tax rates	1,521	2,442	0
Permanent differences	(457)	(205)	98
Research and development	(1,928)	(1,050)	(452)
Return to provision adjustment	327	(67)	28
Change in liability for unrecognized tax benefits	700	(156)	202
Incentive stock option benefit	(77)	(144)	(616)
Change in valuation allowance	1,779	1,200	500
Tax effects of intercompany transactions	630	0	0
Other	(208)	0	(36)
Provision for income taxes	$ 14,200	$ 15,428	$ 12,393
Effective tax rate	45.10%	43.60%	38.40%

Income Taxes - Roll Forward of

Income Taxes - Roll Forward of Liability for Unrecognized Tax Benefits Exclusive of Accrued Interest (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits
Balance, beginning of period	$ 3,396	$ 3,325	$ 3,110
Decrease in previous year tax positions	0	(389)	0
Increase in current year tax positions	448	270	121
Decrease due to lapse of statute of limitations	0	(14)	0
Increase related to adjustment of previous estimates of activity	206	204	94
Balance, end of period	$ 4,050	$ 3,396	$ 3,325

Line of Credit - Additional Inf

Line of Credit - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Total availability under line of credit agreement	$ 10,000,000
Borrowings under the line of credit agreement	0	$ 0
Letters of credit outstanding amount	2,700,000
Available borrowing under letter of credit	$ 7,300,000
Maximum ratio of total liabilities to tangible net worth	1
Minimum required fixed coverage charge ratio	1.25
Period used for calculating ratios	12 months
Company's tangible net worth ratio	1.02
Fixed coverage charge ratio	2.30
LIBOR
Debt Instrument [Line Items]
Line of credit interest rate	1.50%
Prime Rate
Debt Instrument [Line Items]
Line of credit interest rate	0.75%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	1 Months Ended	12 Months Ended			48 Months Ended
	May 31, 2014USD ($)$ / sharesshares	Dec. 31, 2016USD ($)Number_of_stock_repurchase$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2011shares	Dec. 30, 2016$ / shares	Feb. 29, 2016USD ($)	Feb. 26, 2016shares	Dec. 31, 2013$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of repurchase programs authorized | Number_of_stock_repurchase		2
Common stock, par value (in dollars per share) | $ / shares		$ 0.00001	$ 0.00001
Common stock, shares authorized		200,000,000	200,000,000
Preferred stock, shares authorized		25,000,000	25,000,000
Outstanding common stock repurchase program authorized amount | $	$ 30,000,000						$ 50,000,000
Shares repurchased	2,000,000	1,800,000
Additional stock repurchase program authorized amount | $	$ 30,000,000	$ 33,746,000	$ 7,556,000	$ 22,442,000
Remaining authorized repurchase amount | $		16,200,000	0
Tax payments, for net share settlement of share based award | $		1,772,000	1,370,000	1,347,000
Excess tax benefit from stock-based compensation | $		1,438,000	6,936,000	$ 7,985,000
Share based compensation arrangement by share based payment award future tax benefit | $		$ 4,400,000	$ 3,400,000
2016 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future grants								2,000,000
Shares available for future grants		2,700,000
Service Based Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual maturity of plan		10 years
Service Based Restricted Stock Unit | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Service Based Restricted Stock Unit | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		5 years
Performance Based Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual maturity of plan		10 years
Approximate units of performance restricted stock granted (in shares)		79,000	49,000	140,000
Performance criteria met for approximate units (in shares)		100,000
Approximate units outstanding (in shares)		200,000
Incremental stock option expense | $		$ 2,100,000	$ 1,500,000	$ 1,000,000
Performance Based Restricted Stock Unit | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Percentage of targeted shares earned that can vest		0.00%
Performance Based Restricted Stock Unit | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		5 years
Percentage of targeted shares earned that can vest		200.00%
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price on the last trading day of the period (in dollars per share) | $ / shares						$ 24.24
Aggregate intrinsic value, RSUs vested | $		$ 8,400,000
Shares withheld, for net share settlement of share based award		88,289
Tax payments, for net share settlement of share based award | $		$ 1,800,000
Performance criteria met for approximate units (in shares)		414,000	488,000	433,000
Approximate units outstanding (in shares)		1,330,000	1,139,000	1,226,000					1,279,000
Unrecognized stock-based compensation expense related to non-vested stock options | $		$ 20,200,000
Weighted average period		2 years 8 months 16 days
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of options exercised | $		$ 2,000,000	$ 13,600,000	$ 20,200,000
Aggregate intrinsic value, option outstanding | $		19,000,000
Aggregate intrinsic value, options exercisable | $		$ 18,400,000
Number of options outstanding (in shares)		1,008,000	1,103,000	1,641,000					3,366,000
Weighted average exercise price (in dollars per share) | $ / shares		$ 5.40	$ 5.37	$ 5.26					$ 6.15
New option granted (in shares)		0	0	0
Options expected to vest, end of year (in shares)		25,000
Non-Vested Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)		30,600
Weighted average exercise price (in dollars per share) | $ / shares		$ 4.75
Weighted average fair value (in dollars per share) | $ / shares		$ 2.58
Weighted average remaining contractual life		2 years
Aggregate intrinsic value of unvested options | $		$ 600,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental stock option expense | $		$ 0	$ 100,000	$ 0
Number of options outstanding (in shares)		200,000
New option granted (in shares)					1,000,000
Unvested performance options (in shares)		30,600
Unvested share, expected to vest (in shares)		25,000
Options expected to vest, end of year (in shares)		200,000
Fair value of performance-based stock options outstanding and expected to vest | $		$ 600,000
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental stock option expense | $		0	54,000	28,000
Non Qualified Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit recorded | $		$ 200,000	$ 200,000	$ 700,000
Repurchase of Equity
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average cost of repurchase (in dollars per share) | $ / shares	$ 14.85	$ 18.90

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock Units (RSUs) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding
Number of Units outstanding, beginning of year (in shares)	1,139,000	1,226,000	1,279,000
Number of Units, Granted (in shares)	718,000	516,000	554,000
Number of Units, Released (in shares)	(414,000)	(488,000)	(433,000)
Number of Units, Forfeited (in shares)	(113,000)	(115,000)	(174,000)
Number of Units outstanding, end of year (in shares)	1,330,000	1,139,000	1,226,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year (in dollars per share)	$ 19.30	$ 13.23	$ 9.67
Weighted Average Grant Date Fair Value, Granted (in dollars per share)	19.75	26.18	16.98
Weighted Average Grant Date Fair Value, Released (in dollars per share)	15.91	11.82	7.61
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)	21.65	16.72	13.08
Weighted Average Grant Date Fair Value, Units outstanding, end of year (in dollars per share)	$ 20.40	$ 19.30	$ 13.23
Aggregate intrinsic value at year end	$ 32,239

Stockholders' Equity - Summar70

Stockholders' Equity - Summary of the Company's Stock Options Activity (Detail) - Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding
Number of Options outstanding, beginning of year (in shares)	1,103,000	1,641,000	3,366,000
Number of Options, Granted (in shares)	0	0	0
Number of Options, Exercised (in shares)	(95,000)	(525,000)	(1,644,000)
Number of Options, Expired / terminated (in shares)	0	(13,000)	(81,000)
Number of Options outstanding, end of year (in shares)	1,008,000	1,103,000	1,641,000
Number of Options exercisable, end of year (in shares)	977,000	1,072,000	1,606,000
Number of Options expected to vest, end of year (in shares)	25,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price, Options outstanding, beginning of year (in dollars per share)	$ 5.37	$ 5.26	$ 6.15
Weighted Average Exercise Price, Granted (in dollars per share)	0	0	0
Weighted Average Exercise Price, Exercised (in dollars per share)	5.02	4.95	6.69
Weighted Average Exercise Price, Expired / terminated (in dollars per share)	0	7.27	16.59
Weighted Average Exercise Price, Options outstanding, end of year (in dollars per share)	5.40	5.37	5.26
Weighted Average Exercise Price, Options exercisable, end of year (in dollars per share)	5.42	5.39	5.27
Weighted Average Exercise Price, Options expected to vest, end of year (in dollars per share)	$ 4.75

Stockholders' Equity - Summar71

Stockholders' Equity - Summary of Stock Options Outstanding and Exercisable (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, lower limit (in dollars per share)	$ 4
Range of Exercise Price, Upper limit (in dollars per share)	5
Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, lower limit (in dollars per share)	5.01
Range of Exercise Price, Upper limit (in dollars per share)	7
Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, lower limit (in dollars per share)	7.01
Range of Exercise Price, Upper limit (in dollars per share)	10
Range Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, lower limit (in dollars per share)	10.01
Range of Exercise Price, Upper limit (in dollars per share)	16.23
Range Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, lower limit (in dollars per share)	4
Range of Exercise Price, Upper limit (in dollars per share)	$ 16.23
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding (in shares)	1,008,000	1,103,000	1,641,000	3,366,000
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 5.40	$ 5.37	$ 5.26	$ 6.15
Number of Options Exercisable (in shares)	977,000	1,072,000	1,606,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 5.42	$ 5.39	$ 5.27
Stock Options | Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding (in shares)	722,000
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 4.65
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 7 months 28 days
Number of Options Exercisable (in shares)	691,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 4.64
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 8 months 9 days
Stock Options | Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding (in shares)	112,000
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 5.57
Options Outstanding, Weighted Average Remaining Contractual Life	1 year 8 months 12 days
Number of Options Exercisable (in shares)	112,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 5.57
Options Exercisable, Weighted Average Remaining Contractual Life	1 year 8 months 12 days
Stock Options | Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding (in shares)	106,000
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 7.25
Options Outstanding, Weighted Average Remaining Contractual Life	1 year 2 months 9 days
Number of Options Exercisable (in shares)	106,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 7.25
Options Exercisable, Weighted Average Remaining Contractual Life	1 year 2 months 9 days
Stock Options | Range Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding (in shares)	68,000
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 10.30
Options Outstanding, Weighted Average Remaining Contractual Life	4 months 24 days
Number of Options Exercisable (in shares)	68,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 10.30
Options Exercisable, Weighted Average Remaining Contractual Life	4 months 24 days
Stock Options | Range Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding (in shares)	1,008,000
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 5.40
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 3 months
Number of Options Exercisable (in shares)	977,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 5.42
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 3 months

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 9,369	$ 7,263	$ 5,579
Cost of products sold and services delivered
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	342	402	204
Sales, general and administrative expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	5,707	4,285	3,555
Research and development expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 3,320	$ 2,576	$ 1,820

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Officer - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Consulting
Related Party Transaction [Line Items]
Transaction expenses incurred by parent company	$ 200,000	$ 200,000	$ 200,000
Outstanding payables due to related party	12,000	31,000
Software Licensing and Subscription
Related Party Transaction [Line Items]
Annual payments	100,000
Deferred costs related to annual subscription	$ 50,500	$ 36,000

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Company's contributions to the plan	$ 1,600	$ 1,200	$ 900
Deferral percentage of base salary (up to)	80.00%
Deferral percentage of other compensation (up to)	100.00%
Employee deferrals deemed vested percentage upon contribution	100.00%
Company's expected contributions to the plan	$ 32

Business Acquisitions (Details)

Business Acquisitions (Details) - USD ($)	Dec. 30, 2016	Jul. 16, 2015	May 05, 2015	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill					$ 10,442,000	$ 9,596,000
MediaSolv Solutions Corporation
Business Acquisition [Line Items]
Total purchase price			$ 8,800,000	$ 1,000,000	1,500,000	200,000
Cash acquired			100,000
Payments to acquire businesses, net			7,800,000
Contingent liability			1,000,000
Additional earn-out provisions and compensation adjustments			4,000,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable and other current assets			590,000
Inventory			35,000
Property and equipment			53,000
Intangible assets			4,145,000
Goodwill			5,496,000
Accounts payable and accrued liabilities			(697,000)
Deferred revenue			(111,000)
Deferred income tax liabilities, net			(688,000)
Total purchase price			$ 8,823,000
Intangible assets, weighted average useful life			6 years 6 months
Acquisition transaction costs			$ 200,000
MediaSolv Solutions Corporation | Accrued Liabilities
Business Acquisition [Line Items]
Contingent liability					200,000
Tactical Safety Responses Limited
Business Acquisition [Line Items]
Total purchase price		$ 3,300,000
Cash acquired		700,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable and other current assets		726,000
Inventory		497,000
Property and equipment		583,000
Other Assets		20,000
Intangible assets		881,000
Goodwill		1,441,000
Accounts payable and accrued liabilities		(207,000)
Notes payable		(169,000)
Deferred income tax liabilities, net		(438,000)
Total purchase price		$ 3,334,000
Intangible assets, weighted average useful life		7 years
Acquisition transaction costs		$ 100,000
Cash payments to acquire businesses		$ 4,000,000
Tactical Safety Responses Limited | Sales, general and administrative expenses
Business Acquisition [Line Items]
Contingent liability					$ 100,000	$ 0
Axon Artificial Intelligence
Business Acquisition [Line Items]
Contingent liability	$ 3,300,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets	5,210,000
Goodwill	1,615,000
Total purchase price	$ 6,825,000
Intangible assets, weighted average useful life	5 years
Cash payments to acquire businesses	$ 3,500,000

Segment Data - Additional Infor

Segment Data - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Segment Data - Summary of Opera

Segment Data - Summary of Operational Information Relative to the Company's Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Product sales	$ 82,077	$ 71,882	$ 58,756	$ 55,530	$ 56,041	$ 50,376	$ 46,713	$ 44,762	$ 238,573	$ 185,230	$ 160,313
Service revenue									29,672	12,662	4,212
Net sales									268,245	197,892	164,525
Cost of products sold									91,536	65,022	60,913
Cost of services delivered									6,173	4,223	2,064
Gross margin	$ 49,770	$ 46,565	$ 37,299	$ 36,902	$ 36,988	$ 31,068	$ 30,723	$ 29,868	170,536	128,647	101,548
Sales, general and administrative									108,076	69,698	54,158
Research and development									30,609	23,614	14,885
Income from operations									31,851	35,335	32,505
Purchase of property and equipment									4,957	6,003	2,505
Purchase of intangible assets									3,495	501	183
Purchase of intangible assets in connection with business acquisitions									6,825
Purchase of property and equipment and intangible assets in connection with business acquisitions										12,599
Depreciation and amortization									3,658	3,291	4,317
TASER Weapons
Segment Reporting Information [Line Items]
Product sales									202,644	162,375	145,613
Service revenue									0	0	0
Net sales									202,644	162,375	145,613
Cost of products sold									61,930	48,821	47,680
Cost of services delivered									0	0	0
Gross margin									140,714	113,554	97,933
Sales, general and administrative									63,617	47,640	42,989
Research and development									5,887	4,470	3,872
Income from operations									71,210	61,444	51,072
Purchase of property and equipment									4,129	4,159	2,233
Purchase of intangible assets									262	277	180
Purchase of intangible assets in connection with business acquisitions									0
Purchase of property and equipment and intangible assets in connection with business acquisitions										1,453
Depreciation and amortization									2,207	2,311	3,936
Axon
Segment Reporting Information [Line Items]
Product sales									35,929	22,855	14,700
Service revenue									29,672	12,662	4,212
Net sales									65,601	35,517	18,912
Cost of products sold									29,606	16,201	13,233
Cost of services delivered									6,173	4,223	2,064
Gross margin									29,822	15,093	3,615
Sales, general and administrative									44,459	22,058	11,169
Research and development									24,722	19,144	11,013
Income from operations									(39,359)	(26,109)	(18,567)
Purchase of property and equipment									828	1,844	272
Purchase of intangible assets									3,233	224	3
Purchase of intangible assets in connection with business acquisitions									6,825
Purchase of property and equipment and intangible assets in connection with business acquisitions										11,146
Depreciation and amortization									$ 1,451	$ 980	$ 381

Selected Quarterly Financial 78

Selected Quarterly Financial Data (unaudited) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 82,077	$ 71,882	$ 58,756	$ 55,530	$ 56,041	$ 50,376	$ 46,713	$ 44,762	$ 238,573	$ 185,230	$ 160,313
Gross margin	49,770	46,565	37,299	36,902	36,988	31,068	30,723	29,868	170,536	128,647	101,548
Net income	$ 6,341	$ 3,843	$ 3,650	$ 3,463	$ 5,104	$ 1,521	$ 6,103	$ 7,205	$ 17,297	$ 19,933	$ 19,918
Earnings per share
Basic (in dollars per share)	$ 0.12	$ 0.07	$ 0.07	$ 0.06	$ 0.10	$ 0.03	$ 0.11	$ 0.14	$ 0.33	$ 0.37	$ 0.38
Diluted (in dollars per share)	$ 0.12	$ 0.07	$ 0.07	$ 0.06	$ 0.09	$ 0.03	$ 0.11	$ 0.13	$ 0.32	$ 0.36	$ 0.37

Supplemental Disclosure to Ca79

Supplemental Disclosure to Cash Flows - Summary of Supplemental Non-Cash and Other Cash Flow Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash paid for income taxes, net of refunds	$ 14,048	$ 6,759	$ 386
Non-cash transactions:
Contingent consideration related to business combinations	3,325	952	0
Property and equipment purchases in accounts payable	82	315	270
Purchase of assets under capital lease obligations	$ 134	$ 0	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - Dextro - Subsequent Event	Feb. 09, 2017USD ($)
Subsequent Event [Line Items]
Cash payments to acquire businesses	$ 7,100,000
Contingent earn outs	$ 1,100,000

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Allowance for Doubtful Accounts
Movement in Valuation Allowances and Reserves
Balance at Beginning of Period	$ 322	$ 251	$ 200
Charged to Costs and Expenses	205	86	142
Charged to Other Accounts	0	0	0
Deductions	(84)	(15)	(91)
Balance at End of Period	443	322	251
Warranty Reserve
Movement in Valuation Allowances and Reserves
Balance at Beginning of Period	314	675	955
Charged to Costs and Expenses	621	(62)	396
Charged to Other Accounts	0	0	0
Deductions	(155)	(299)	(676)
Balance at End of Period	$ 780	$ 314	$ 675